Papers
On this page you will find the papers from:
2012
Attema AE, Brouwer WBF. A test of independence of discounting from quality of life. Journal of Health Economics 31 (2012) 22-34.
Attema AE, Brouwer WBF. Constantly Proving The Opposite? A test of CPTO using a broad time horizon and correcting for discounting. Qual Life Res (2012) 21:25-34. DOI 10.1007/s11136-011-9917-4.
Frederix GWJ, Severens JL, Hövels AM, Raaijmakers JAM, Schellens JHM. Reviewing the Cost-Effectiveness of Endocrine Early Breast Cancer Therapies: Influence of Differences in Modeling Methods on Outcomes. Value in Health (2012) 94-105.
van Gestel A, Grutters J, Schouten J, Webers C, Beckers H, Joore M, Severens J. The Role of the Expected Value of Individualized Care inCost-Effectiveness Analyses and Decision Making. Value in Health (2012) 13–21.
van Gestel A, Webers CA, Severens JL, Beckers HJ, Jansonius NM, Hendrikse F, Schouten JS. The long-term outcomes of four alternative treatment strategies for primary open-angle glaucoma. Acta Ophthalmol. 2012: 90: 20-31.
Hoomans T, Severens JL, van der Roer N, Delwel GO. Methodological Quality of Economic Evaluations of New Pharmaceuticals in the Netherlands. Pharmacoeconomics 2012; 30 (3): 219-227.
van de Kassteele J, Hoogenveen RT, Engelfriet PM, van Baal PHM, Boshuizen HC. Estimating net transition probabilities from cross-sectional data with application to risk factors in chronic disease modeling. Statistics in Medicine 2012, 31 533–543.
Koopmanschap MA. Generic medicine pricing: on track in Europe? GaBi Journal (2012) 1, 5.
Niëns LM, Cameron A, van de Poel E, Ewen M, Laing R, Brouwer WBF. Practical measurement of affordability: an application to medicines. Bulletin of the World Health organization 2012, 90(2): 219-227.
van de Poel E, O'Donnell O, Van Doorslaer E. Is there a health penalty of China's rapid urbanization? Health Economics 21 (2012) 367-385.
Rutten-van Mölken MPMH, Goossens LMA. Cost Effectiveness of Pharmacological Maintenance Treatment for Chronic Obstructive Pulmonary Disease. A Review of the Evidence and Methodological Issues. Pharmacoeconomics 2012; 30 (4): 1-32.
Tan SS, Bakker J, Hoogendoorn ME, Kapila A, Martin J, Pezzi A, Pittoni G, Spronk PE, Welte R, Hakkaart-van Roijen L. Direct Cost Analysis of Intensive Care Unit Stay in Four European Countries: Applying a Standardized Costing Methodology. Value in Health 15 (2012) 81-86.
Tan SS, Bouwmans CAM, Rutten FFH, Hakkaart-van Roijen L. Update of the Dutch Manual for Costing in Economic Evaluations. International Journal of Technology Assessment in Health Care, 28:2 (2012), 152–158.
Zhang W, Bansback N, Boonen A, Severens JL, Anis AH. Development of a Composite Questionnaire, the Valuation of Lost Productivity, to Value Productivity Losses: Application in Rheumatoid Arthritis. Value in Health 15 (2012) 46–54.
2011
Agyemang C, Kunst A, Bhopal R, Zaninotto P, Nazroo J, Nicolau M, Unwin N, van Valkengoed I, Redekop K, Stronks K. Dutch versus English advantage in the epidemic of central and generalised obesity is not shared by ethnic minority groups: comparative secondary analysis of cross-sectional data. International Journal of Obesity (2011) 35, 1334-1346.
Agyemang C, Kunst AE, Bhopal R, Anujuo K, Zaninotto P, Nazroo J, Nicolaou M, Unwin N, van Valkengoed I, Redekop WK, Stronks K. Diabetes Prevalence in Populations of South Asian Indian and African Origins: A Comparison of England and The Netherlands. Epidemiology. 2011 Jul;22(4):563-567.
Agyemang C, Kunst AE, Bhopal RAJ, Zaninotto P, Unwin N, Nazroo J, Nicolaou M, Redekop WK, Stronks K. Hypertensie in Nederlandse en Engelse etnische minderheidsgroepen. Bloeddruk in engelse groepen beter onder controle dan in nederlandse. Nederlands Tijdschrift voor Geneeskunde 2011; 155:A3318.
Agyemang C, Kunst AE, Bhopal R, Zaninotto P, Unwin N, Nazroo J, Nicolaou M, Redekop WK, Stronks K. Hypertension in Dutch and English ethnic minorities. Blood pressure better controlled in English groups than in Dutch groups. Ned Tijdschr Geneeskd. 2011;155(18):A3318.
Albers-Heitner PC, Lagro-Janssen TA, Joore MM, Berghmans BL, Nieman FF, Venema PP, Severens JJ, Winkens RR. Effectiveness of involving a nurse specialist for patients with urinary incontinence in primary care: results of a pragmatic multicentre randomised controlled trial. Int J Clin Pract. 2011 Jun;65(6):705-712.
Alemao E, Rajagopalan S, Yang S, Curiel RE, Purvis J, Al MJ. Inverse probability weighting to control for censoring in a post hoc analysis of quality-adjusted survival data from a clinical trial of temsirolimus for renal cell carcinoma. Journal of Medical Economics Vol. 14, No. 2, 2011, 245-252.
van Baal P, Brouwer W. PAID 1.0 in Practice: A Brief Clarification Regarding its Possibilities and Limitations. Pharmacoeconimcs (2011). doi: 10.2165/11585600-000000000-00000.
van Baal PH, Engelfriet PM, Hoogenveen RT, Poos MJ, van den Dungen C, Boshuizen HC. Estimating and comparing incidence and prevalence of chronic diseases by combining GP registry data: the role of uncertainty. BMC Public Health. 2011 Mar 15;11:163.
van Baal PH, Engelfriet PM, Boshuizen HC, van de Kassteele J, Schellevis FG, Hoogenveen RT. Co-occurrence of diabetes, myocardial infarction, stroke, and cancer: quantifying age patterns in
the Dutch popuation using health survey data. Population Health Metrics 2011, 9:51.
van Baal PH, Wong A, Slobbe LC, Polder JJ, Brouwer WB, de Wit GA. Standardizing the inclusion of indirect medical costs in economic evaluations. Pharmacoeconomics. 2011 Mar 1; 29(3): 175-87.
Baeten SA, Baltussen RMPM, Uyl-de Groot CA, Bridges JFP, Niessen LW. Reducing Disparities in Breast Cancer Survival. The Effect of Large-Scale Screening of the Uninsured. The Breast Journal, Volume 17 Number 5, 2011 548-549.
van den Berg M, Smit F, Vos T, van Baal P.H.M. Cost-Effectiveness of Opportunistic Screening and Minimal Contact Psychotherapy to Prevent Depression in Primary Care Patients. PLoS ONE 1 August 2011, Volume 6, Issue 8, e22884.
van den Berg IM, Eleveld C, van der Hoeven M, Birnie E, Steegers AEP, Galjaard RJ, Laven JSE, van Doorninck JH. Defective deacetylation of histone 4 K12 in human oocytes is associated with advanced maternal age and chromosome misalignment. DOI:10.1093/humrep/der030
van den Berg TI, Robroek SJ, Plat JF, Koopmanschap MA, Burdorf A. The importance of job control for workers with decreased work ability to remain productive at work. DOI 10.1007/s00420-010-0588-1
Bijlenga D, Koopmans CM, Birnie E, Mol BW, van der Post JA, Bloemenkamp KW, Scheepers HC, Willekes C, Kwee A, Heres MH, Van Beek E, Van Meir CA, Van Huizen ME, Van Pampus MG, Bonsel GJ.Health-related quality of life after induction of labor versus expectant monitoring in gestational hypertension or preeclampsia at term. DOI: 10.3109/10641955.2010.486458
Boonen A, Severens JL. Evaluating treatment strategies in patients with early rheumatoid arthritis: merging modeling theory with clinical practice. J Rheumatol. 2011 Aug;38(8):1538-40.
Camejo RR, McGrath C, Herings R, Meerding W-J, Rutten F. Antihypertensive Drugs: A Perspective on Pharmaceutical Price Erosion and Its Impact on Cost-Effectiveness. Value in Health. Oktober 2011. doi:10.1016/j.jval.2011.08.1736.
Cramm JM, Strating MMH, Tsiachristas A, Nieboer AP. Development and validation of a short version of the Assessment of Chronic Illness Care (ACIC) in Dutch Disease Management Programs. Health Qual Life Outcomes. 2011; 9:49. doi: 10.1186/1477-7525-9-49.
Christiaans I, Birnie E, Bonsel GJ, Mannens MMAM, Michels M, Majoor-Krakauer D, Dooijers D, van Tinelen P, van den Berg PM, Volders PGA, Arens YH, van den Wijngaard A, Atsma DE, Helderman-van den Enden ATJM, Houweling AC, de Boer K, van der Smagt JJ, Hauer RNW, Marcelis CLM, Timmermans J, van Langen IM, Wilde AAM. Manifest disease, risk factors for sudden cardiac death, and cardiac events in a large nationwide cohort of predictively tested hypertrophic cardiomyopathy mutation carriers: determining the best cardiological screening strategy. doi:10.1093/eurheartj/ehr092
Drummond M, Jönsson B, Rutten F, Stargardt T. Reimbursement of pharmaceuticals: reference pricing versus health technology assessment. Eur J Health Econ. 2011 Jun;12(3):263-71. Epub 2010 Aug 28.
Engelfriet PM, Hoogenveen RT, Boshuizen HC, van Baal PH. To die with or from heart failure: a difference that counts: Is heart failure underrepresented in national mortality statistics? Eur J Heart Fail. 2011 Apr;13(4):377-83.
van Es PP, Luisterburg PAJ, Dekker J, Koopmanschap MA, Bohnen AM, Verhaar JAN, Koes BW, Bierma-Zeinstra SMA. Cost-effectiveness of exercise therapy versus general practitioner care for osteoarthritis of the hip: design of a randomised clinical trial. BMC Musculoskeletal Disorders 2011.
Feenstra TL, van Baal PM, Jacobs-van der Bruggen MO, Hoogenveen RT, Kommer GJ, Baan CA. (2011) Targeted versus universal prevention. a resource allocation model to prioritize cardiovascular prevention. Cost Eff Resour Alloc. 2011 Oct 6;9(1):14.
Gaultney JG, Redekop WK, Sonneveld P, Uyl-de Groot, C. Critical review of economic evaluations in multiple myeloma: An overview of the economic evidence and quality of the methodology. European Journal of Cancer 47 (2011) 1458-1467.
Gaultney JG, Sanhueza E, Janssen JJ, Redekop WK, Uyl-de Groot CA. Application of cost-effectiveness analysis to demonstrate the potential value of companion diagnostics in chronic myeloid leukemia. Pharmacogenomics (2011);12(3);1-11.
van Gestel A, Webers CA, Beckers HJ, van Dongen MC, Severens JL, Hendrikse F, Schouten JS. The relationship between visual field loss in glaucoma and health-related quality-of-life. Eye (Lond). 2010 Dec;24(12):1759-69. Epub 2010 Nov 5.
Goossens LMA, Baker CL, Monz BU, Zou KH, Rutten-van Mölken MPMH. Adjusting for COPD severity in database research: developing and validating an algorithm. International Journal of COPD. 2011 Dec 5. DOI: http://dx.doi.org/10.2147/COPD.S26214.
Goossens LMA, Nivens MC, Sachs P, Monz BU, Rutten-van Molken PMH. Is the EQ-5D responsive to recovery from a moderate COPD exacerbation? Respiratory Medicine (2011) 105, 1195-1202.
Harford JB, Otero IV, Anderson BO, Cazap E, Gradishar WJ, Gralow JR, Kane GM, Niëns LM, Porter PL, Reeler AV, Rieger PT, Shockney LD, Shulman LN, Soldak T, Thomas DB, Thompson B, Winchester DP, Zelle SG, Badwe RA. Problem solving for breast health care delivery in low and middle resource countries (LMCs): consensus statement from the Breast Health Global Initiative. Breast. 2011 Apr;20 Suppl 2:S20-9. Epub 2011 Mar 4.
Heijink R, van Baal P, Oppe M, Koolman X, Westert G. Decomposing cross-country differences in quality adjusted life expectancy: the impact of value sets. Popul Health Metr. 2011 Jun 23;9(1):17.
Hendriks M, Brewster L, Wit F, Bolarinwa OA, Odusola AO, Redekop W, Bindraban N, Vollaard A, Alli S, Adenusi P, Agbede K, Akande T, Lange J, Schultsz C. Cardiovascular disease prevention in rural Nigeria in the context of a community based health insurance scheme: Qualtiy Improvement Cardiovascular care Kwara-I (Quick-I). BMC Public Health 2011, 11:186.
Hoogendoorn M, Hoogenveen RT, Rutten-van Molken MP, Vestbo J, Feenstra TL. Case fatality of COPD exacerbations: a meta-analysis and statistical modelling approach. European Respiratory Journal 2011; 37: 508-515. DOI: 10.1183/09031936.00043710.
Hoogendoorn M, Rutten-van Mölken MPMH, Hoogenveen RT, Al MJ, Feenstra TL. Developing and Applying a Stochastic Dynamic Population Model for Chronic Obstructive Pulmonary Disease. Value in Health. Volume 14, Issue 8, December 2011, Pages 1039-1047. doi:10.1016/j.jval.2011.06.008.
Hoogveldt B, Rive B, Severens J, Maman K, Guilhaume C. Cost-effectiveness analysis of memantine for moderate-to-severe Alzheimer's disease in the Netherlands. Neuropsychiatric Disease and Treatment (2011). doi: 10.2147/NDT.S19239.
Hoefman RJ, van Exel NJ, Foets M, Brouwer WB. 2011. Sustained informal care: The feasibility, construct validity and test-retest reliability of the CarerQol-instrument to measure the impact of informal care in long-term care. Aging & Mental Health. Nov;15(8):1018-27.
Hoefman RJ, Exel, van NJA, Jong, de SL, Redekop WK, Brouwer WBF. A new test of the construct validity of the CarerQol instrument: measuring the impact of informal care giving. Quality of Life Reseach 2011 20:875-887
Hoomans T, Ament AJ, Evers SM, Severens JL. Implementing guidelines into clinical practice: what is the value? J Eval Clin Pract. 2011 Aug;17(4):606-614. Epub 2010 Oct 4.
Kanters TA, Hagemans MLC, van der Beek NAME, Rutten FFH, van der Ploeg AT, Hakkaart L. Burden of illness of Pompe disease in patients only receiving supportive care. Journal of Inherited Metabolic Disease. doi: 10.1007/s10545-011-9320-x.
van de Kassteele J, Hoogenveen RT, Engelfriet PM, van Baal PH, Boshuizen HC. Estimating net transition probabilities from cross-sectional data with application to risk factors in chronic disease modeling. Stat Med. 2011 Dec 5. doi: 10.1002/sim.4423. [Epub ahead of print]
Koedoot C, Bouwmans C, Franken MC, Stolk E. Quality of life in adults who stutter. Journal of Communication Disorders. doi:10.1016/j.jcomdis.2011.02.002.
Koedoot C, Versteegh M, Yaruss JS. Psychometric evaluation of the Dutch translation of the Overall Assessment of the Speaker's Experience of Stuttering for adults (OASES-A-D). Journal of Fluency Disorders. doi:10.1016/j.jfludis.2011.03.002.
Krol M, Papenburg J, Koopmanschap M, Brouwer M. Do productivity costs matter? The impact of including productivity costs on the incremental costs of interventions targeted at depressive disorders. Pharmacoeconomics (2011). doi: 10.2165/11539970-000000000-00000.
Lemmens KM, Rutten-Van Mölken MP, Cramm JM, Huijsman R, Bal RA, Nieboer AP. Evaluation of a large scale implementation of disease management programmes in various Dutch regions: a study protocol. BMC Health Serv Res. 2011 Jan 10;11(1):6.
Majer IM, Nusselder WJ, Mackenbach JP, Klijs B, van Baal PH Mortality Risk Associated With Disability: A Population-Based Record Linkage Study. Am J Public Health. 2011 Oct 20
De Meijer C, Koopmanschap M, D' Uva TB, van Doorslaer E. Determinants of long-term care spending: Age, time to death or disability? J Health Econ. 2011 Mar;30(2):425-38. Epub 2011 Jan 13.
Oppe M, Al M, Rutten-van Molken, M. Comparing Methods of Data Synthesis. Re-Estimating Parameters of an Existing Probabilistic Cost-Effectiveness Model (2011). Pharmacoeconomics 2011; 29 (3): 239-250.
Petrillo J, van Nooten F, Jones P, Rutten-van Molken M. Utility Estimation in Chronic Obstructive Pulmonary Disease. Pharmacoeconomics 2011; 29 (11): 917-932.
Poeran J, Denktas S, Birnie E, Bonsel GJ, Steegers EAP. Urban perinatal health inequalities.The Journal of Maternal-Fetal and Neonatal Medicine, April 2011; 24(4): 643–646
Ramos GFP, Kuiper S, Dompeling E, van Asselt ADI, de Grauw WJC, Knottnerus JA, van Schayck OCP, Schermer TRJ, Severens JL. Structuring and validating a cost-effectivenessmodel of primary asthma prevention amongst children. BMC Medical Research Methodology 2011, 11:150.
van Steenbergen-Weijenburg KM, van Puffelen AL, Horn EK, Nuyen J, van Dam PS, van Benthem TB, Beekman AT, Rutten FF, Hakkaart-van Roijen L, van der Feltz-Cornelis CM. More co-morbid depression in patients with Type 2 diabetes with multiple complications. An observational study at a specialized outpatient clinic. Diabet Med. 2011 Jan;28(1):86-9.
Tan SS, Van Putten E, Nijdam WM, Hanssens P, Beute GN, Nowak PJ, Dirven CM, Hakkaart-van Roijen L. A microcosting study of microsurgery, LINAC radiosurgery, and gamma knife radiosurgery in meningioma patients. J Neurooncol. 2011 Jan;101 (2): 237-45. Epub 2010 Jun 6.
Tielen M, van Exel NJ, van Buren MC, Maasdam L, Weimar W. Attitudes towards medication non-adherence in elderly kidney transplant patients: a Q methodology study. Nephrol Dial Transplant. 2011 May;26(5):1723-8. Epub 2010 Oct 12.
Timmermans S, Bonsel GJ, Steegers-Theunissen RPM, Mackenbach JP, Steyerberg EW, Raat H, Verbrugh HA, Tiemeier HW, Hofman A, Birnie E, Looman CWN, Jaddoe, VWV, Steegers EAP. Individual accumulation of heterogeneous risks explains perinatal inequalities within deprived neighbourhoods. DOI 10.1007/s10654-010-9542-5
Tsiachristas A, Hipple-Walters B, Lemmens KMM, Nieboer AP, Rutten-van Mölken MPMH. Towards integrated care for chronic conditions: Dutch policy developments to overcome the (financial) barriers. Health Policy. 2011 Jul;101(2):122-32. Epub 2010 Nov 9.
Vemer P, Rutten-van Mölken MPMH. Largely ignored: the impact of the threshold value for a QALY on the importance of a transferability factor. DOI 10.1007/s10198-010-0253-3
Verelst SG, Termorshuizen F, Uyl-de Groot CA, Schaafsma MR, Ammerlaan AH, Wittebol S, Sinnige HA, Zweegman S, van Marwijk Kooy M, van der Griend R, Lokhorst HM, Sonneveld P, Wijermans PW; Dutch-Belgium Hemato-Oncology Cooperative Group (HOVON). Effect of thalidomide with melphalan and prednisone on health-related quality of life (HRQoL) in elderly patients with newly diagnosed multiple myeloma: a prospective analysis in a randomized trial. Ann Hematol. 2011 Apr 7. [Epub ahead of print].
Versteegh MM, Leunis A, Luime JJ, Boggild M, Uyl-de Groot CA, Stolk EA. Mapping QLQ-C30, HAQ, and MSIS-29 on EQ-5D. Med Decis Making published online 22 November 2011. DOI: 10.1177/0272989X11427761.
Vogelmeier C, Hederer B, Glaab T, Schmidt H, Rutten-van Molken MPMH, Beeh KM, Rabe KF, Fabbri LM. Tiotropium versus Salmeterol for the Prevention of Exacerbations of COPD. The New England Journal of Medicine 364;12 March 24, 2011.
2010
Abdellaoui M, Attema AE, Bleichrodt H. Intertemporal tradeoffs for gains and losses: an experimental measurement of discounted utility. Econ J 2009 June, Vol 120: 845-866.
Al MJ, Hakkaart L, Tan SS, Bakker J. Cost-consequence analysis of remifentanil-based analgo-sedation vs. conventional analgesia and sedation for patients on mechanical ventilation in the Netherlands. Journal of Critical Care. 2010 14(195), 10 pp., 1-10.
Attema AE, Bleichrodt H, Rohde KIM, Wakker PP. Time-Tradeoff Sequences for Analyzing Discounting and Time Inconsistency. MANAGEMENT SCIENCE Vol. 56, No. 11, November 2010, pp. 2015–2030.
Attema AE, Brouwer WB. The Value of Correcting Values: Influence and Importance of Correcting TTO Scores for Time Preference. Value Health. 2010 Dec;13(8):879-84.
Attema AE, Lugnér AK, Feenstra TL. Investment in antiviral drugs: a real options approach. Health Econ. 2010 Oct; 19(10): 1240-54 DOI: 10.1002/hec.1549.
Van Baal PHM. Economische evaluaties en de zorgkosten van levensverlenging. VGE Bulletin 2010: 26-28.
Van Baal PHM, Feenstra TL. Long-term effects of alcohol policies: an economic perspective. Addiction 2010; 105: 395-397.
Van Baal PHM, Feenstra TL, Polder JJ, Hoogenveen RT, Brouwer WBF. Economic evaluation and the postponement of health care costs. Health Econ. 2011 Apr;20(4):432-45.
Van Baal PHM, Hoogenveen RT, Engelfriet PM, Boshuizen HC. Indirect estimation of chronic disease excess mortality. Epidemiology 2010; 21: 425-426.
Baeten SA, Baltussen RM, Uyl-de Groot CA, Bridges J, Niessen LW. Incorporating equity-efficiency interactions in cost-effectiveness analysis-three approaches applied to breast cancer control. Value Health. 2010 Aug;13(5):573-9. Epub 2010 Mar 31.
Baeten SA, van Exel NJ, Dirks M, Koopmanschap MA, Dippel DW, Niessen LW. Lifetime health effects and medical costs of integrated stroke services - a non-randomized controlled cluster-trial based life table approach. Cost Eff Resour Alloc. 2010 Nov 17;8:21.
Baker R, Van Exel NJA, Mason H, Stricklin M. Connecting Q & Surveys: Three Methods to Explore Factor Membership in Large Samples. The International Journal of Q Methodology, 2010, 34(1): 38–58.
Berghout CC, Zevalkink J, Hakkaart-van Roijen L. A cost-utility analysis of psychoanalysis versus psychoanalytic psychotherapy. Int J Technol Assess Health Care. 2010 Jan;26(1):3-10.
Berghout CC, Zevalkink J, Hakkaart-Van Roijen L. The effects of long-term psychoanalytic treatment on healthcare utilization and work impairment and their associated costs. J Psychiatr Pract. 2010 Jul;16(4):209-16.
Bijlenga D, Bonsel GJ, Birnie E. Eliciting willingness to pay in obstetrics: comparing a direct and an indirect valuation method for complex health outcomes. Health Econ. 2010 Oct 22. [Epub ahead of print].
Bobinac A, Van Exel NJ, Rutten FF, Brouwer WB. Willingness to pay for a quality-adjusted life-year: the individual perspective. Value Health. 2010 Dec;13(8):1046-55. Epub 2010 Sep 3.
Boormans EM, Birnie E, Knegt AC, Schuring-Blom GH, Bonsel GJ, van Lith JM. Aiming at multidisciplinary consensus: what should be detected in prenatal diagnosis? Prenat Diagn. 2010 Aug 26. [Epub ahead of print].
Boormans EM, Birnie E, Oepkes D, Boekkooi PF, Bonsel GJ, van Lith JM. Individualized choice in prenatal diagnosis: the impact of karyotyping and standalone rapid aneuploidy detection on quality of life. Prenat Diagn. 2010 Oct;30(10):928-36.
Choté AA, De Groot CJ, Bruijnzeels MA, Redekop WK, Jaddoe VW, Hofman A, Steegers EA, Mackenbach JP, Foets M. Ethnic differences in antenatal care use in a large multi-ethnic urban population in the Netherlands. Midwifery.
Christiaans I, Birnie E, Van Langen IM, Van Spaendonck-Zwarts KY, Van Tintelen JP, Van den Berg MP, Atsma DE, Helderman-van den Enden AT, Pinto YM, Hermans-van Ast JF, Bonsel GJ, Wilde AA. The yield of risk stratification for sudden cardiac death in hypertrophic cardiomyopathy myosin-binding protein C gene mutation carriers: focus on predictive screening. Eur Heart J 2010 Apr; 31 (7): 842-8.
Christiaans I, Kok TM, Van Langen IM, Birnie E, Bonsel GJ, Wilde AA, Smets EM. Obtaining insurance after DNA diagnostics: a survey among hypertrophic cardiomyopathy mutation carriers. Eur J Hum Genet 2010; 18: 251-253.
Cleveringa FG, Welsing PM, van den Donk M, Gorter KJ, Niessen LW, Rutten GE, Redekop WK. Cost-effectiveness of the diabetes care protocol, a multifaceted computerized decision support diabetes management intervention that reduces cardiovascular risk. Diabetes Care. 2010 Feb;33(2):258-63. Epub 2009 Nov 23.
Cramm JM, Van Exel NJA, Møller V, Finkenflügel H. Patient Views on Determinants of Compliance with Tuberculosis Treatment in the Eastern Cape, South Africa: An Application of Q-Methodology. The Patient: Patient-Centered Outcomes Research: 1 December 2010 - Volume 3 - Issue 4 - pp 205-206.
Craig BM, Oppe M. From a different angle: a novel approach to health valuation. Soc Sci Med 2010; 70: 169-174.
Denktaş S, Koopmans G, Birnie E, Foets M, Bonsel G. Underutilization of prescribed drugs use among first generation elderly immigrants in the Netherlands. BMC Health Serv Res. 2010 Jun 22;10:176.
Van Dijk M, Poley MJ, Gischler SJ, Mazer P, IJsselstijn H, Tibboel D, Latour JM. Parental satisfaction with follow-up services for children with major anatomical congenital anomalies. Child Care Health Dev 2010; 36: 101-109.
Van Duijn M, Eijkemans MJ, Koes BW, Koopmanschap MA, Burton KA, Burdorf A. The effects of timing on the cost-effectiveness of interventions for workers on sick leave due to low back pain. Occup Environ Med. 2010 Nov;67(11):744-50.
Hakkaart-van Roijen L, Tan SS, Goossens L, Schawo S, Brouwer W, Rutten-van Mölken M, Rutten F. Doelmatigheid in praktijkrichtlijnen voor medicijnen: resultaten van een 'quick scan'. TSG 2010; 4: 175-181.
Van Heesch MM, Bonsel GJ, Dumoulin JC, Evers JL, van der Hoeven MA, Severens JL, Dykgraaf RH, van der Veen F, Tonch N, Nelen WL, van Zonneveld P, van Goudoever JB, Tamminga P, Steiner K, Koopman-Esseboom C, van Beijsterveldt CE, Boomsma DI, Snellen D, Dirksen CD. Long term costs and effects of reducing the number of twin pregnancies in IVF by single embryo transfer: the TwinSing study. BMC Pediatr. 2010 Oct 20;10:75.
Hendrix M, Pavlova M, Nieuwenhuijze MJ, Severens JL, Nijhuis JG. Differences in preferences for obstetric care between nulliparae and their partners in the Netherlands: a discrete-choice experiment. J Psychosom Obstet Gynaecol. 2010 Dec;31(4):243-51.
Hendrix A, van der Werf C, Bots ML, Birnie E, van der Smagt JJ, Borleffs CJ, Vink A, van Weert HC, Doevendans PA, Wilde AA, Mosterd A, van Langen IM. Rationale and design of the CAREFUL study : The yield of CARdiogenetic scrEening in First degree relatives of sudden cardiac and UnexpLained death victims <45 years. Neth Heart J. 2010 Jun;18(6):286-90.
Hoefman RJ, van Exel NJA, Brouwer WBF. Laat zorgverlener bij ouderenzorg samenwerken met vrienden en familie. VGE Bulletin oktober 2010: p 16-18.
Hoefman RJ, van Exel NJ, Looren de Jong S, Redekop WK, Brouwer WB. A new test of the construct validity of the CarerQol instrument: measuring the impact of informal care giving. Qual Life Res. 2011 Jan 1. [Epub ahead of print]
Holtzer-Goor KM, van Sprundel E, Lemij HG, Plochg T, Klazinga NS, Koopmanschap MA. Cost-Effectiveness of Monitoring Glaucoma Patients in Shared Care: an Economic Evaluation alongside a Randomized Controlled Trial. BMC Health Serv Res. 2010 Nov 17;10(1):312.
Hoogendoorn M, Feenstra TL, Hoogenveen RT, Al M, Rutten-van Mölken MP. Association between lung function and exacerbation frequency in patients with COPD. Int J of COPD, Dec 2010.
Hoogendoorn M, Feenstra TL, Hoogenveen RT, Rutten-van Mölken MP. Long-term effectiveness and cost-effectiveness of smoking cessation interventions in patients with COPD. Thorax. 2010 Aug;65(8):711-8.
Hoogendoorn M, Van Wetering CR, Schols AM, Rutten-van Mölken MPMH. Is INTERdisicplinary COMmunity-based COPD management (INTERCOM) cost-effective? Eur Respir J 2010; 35: 79-87.
Hoomans T, van der Roer N, Severens JL, Delwel GO. Kosteneffectiviteit van nieuwe geneesmiddelen. Van belang bij geneesmiddelenvergoeding, maar voor verbetering vatbaar. Ned Tijdschr Geneeskd. 2010;154:A958;p 1-9.
Huijgens PC, Posthuma EFM, Coebergh JWW, van de Poll-Franse LV, Uyl-de Groot CA, Sonneveld P. A 'population based registry' for hemato-oncology. Ned Tijdschr Hematol 2010;7:321-5.
Ista E, Van Dijk M, Gischler S, De Leeuw M, Poley MJ, Tibboel D. Weaning of opioids and benzodiazepines at home after critical illness in infants: a cost-effective approach. J Opioid Manag 2010; 6: 55-62.
Jedeloo S, Van Staa A, Latour JM, Van Exel NJA. Preferences for health care and self-management among Dutch adolescents with chronic conditions: a Q-methodological investigation. Int J Nurs Stud 2010; 47: 593-603.
Van Keulen HM, Bosmans JE, van Tulder MW, Severens JL, de Vries H, Brug J, Mesters I. Cost-effectiveness of tailored print communication, telephone motivational interviewing, and a combination of the two: results of an economic evaluation alongside the Vitalum randomized controlled trial. Int J Behav Nutr Phys Act. 2010 Sep 3;7:64.
Van der Kooij SM, Hehenkamp WJ, Volkers NA, Birnie E, Ankum WM, Reekers JA. Uterine artery embolization vs hysterectomy in the treatment of symptomatic uterine fibroids: 5-year outcome from the randomized EMMY trial. Am J Obstet Gynecol 2010; 203(2): 105.e1-13.
Koopmanschap M, de Meijer C, Wouterse B, Polder J. Determinants of Health Care Expenditure in an Aging Society. Arch Phys Med Rehabil. 1992 Jun;73(6):582-6.
Koopmanschap MA, Stolk EA, Koolman X. Dear policy maker: have you made up your mind? A discrete choice experiment among policy makers and other health professionals. Int J Technol Assess Health Care 2010; 26: 198-204.
De Korte D, van Schayck OCP, van Spiegel P, Kaptein AA, Sachs A, Rutten-van Mölken M, Chavannes N, Tromp-Beelen T, Bes R, Allard R, Peeters G, Kliphuis L, Schouten JW, van Gennip L, van Ommen R, Asin J. Supporting smoking cessation in healthcare: obstacles in scientific understanding and tobacco addiction management. Health Vol.2, No.11, 1272-1279 (2010).
Lenoir-Wijnkoop I, Dapoigny M, Dubois D, van Ganse E, Gutiérrez-Ibarluzea I, Hutton J, Jones P, Mittendorf T, Poley MJ, Salminen S, Nuijten MJ. Nutrition economics - characterising the economic and health impact of nutrition. Br J Nutr. 2011 Jan;105(1):157-66.
Le Polain M, Franken M, Koopmanschap M, Cleemput I. Drug reimbursement systems: international comparison and policy recommendations. KCE reports 147C.
Lemmens KM, Nieboer AP, Rutten-van Mölken MPMH, Van Schayck CP, Asin JD, Dirven JA, Huijsman R. Application of a theoretical model to evaluate COPD disease management. BMC Health Serv Res 2010; 10: 81.
McLaughlin T, Buxton M, Mittendorf T, Redekop W, Mucha L, Darba J, Jonsson L, Lacey L, Leibman C. Assessment of potential measures in models of progression in Alzheimer disease. Neurology. 2010 Oct 5;75(14):1256-62.
De Meijer C, Brouwer WBF, Koopmanschap MA, Van den Berg B, Van Exel NJA. The value of informal care: a further investigation of the feasibility of contingent valuation in informal caregivers. Health Econ 2009 Jun 23.
Nieboer AP, Koolman X, Stolk EA. Preferences for long-term care services: willingness to pay estimates derived from a discrete choice experiment. Soc Sci Med 2010; 70: 1317-1325.
Niëns LM, Cameron A, Van de Poel E, Ewen M, Brouwer WBF, Laing R. Quantifying the Impoverishing Effects of Purchasing Medicines: A Cross-Country Comparison of the Affordability of Medicines in the Developing World. PLoS Med. 2010 Aug 31; 7(8). pii: e1000333.
Olieman JF, Poley MJ, Gischler SJ, Penning C, Escher JC, Van den Hoonaard TL, Van Goudoever JB, Bax NMA, Tibboel D, IJsselstijn H. Interdisciplinary management of infantile short bowel syndrome: resource consumption, growth, and nutrition. J Pediatr Surg 2010; 45: 490-498.
Van de Poel E, Speybroeck N. Decomposing malnutrition inequalities between Scheduled Castes and Tribes and the remaining Indian population. Ethn Health. 2009 Jun;14(3):271-87.
Poeran J, Denktas S, Birnie E, Bonsel GJ, Steegers EA. Urban perinatal health inequalities. J Matern Fetal Neonatal Med. 2010 Sep 14. [Epub ahead of print]
Rappange DR, Brouwer WBF, Rutten FFH, Van Baal PHM. Lifestyle intervention: from cost savings to value for money. J Public Health 2009 Aug 7.
Van Steenbergen-Weijenburg KM, van der Feltz-Cornelis CM, Horn EK, van Marwijk HW, Beekman AT, Rutten FF, Hakkaart-van Roijen L. Cost-effectiveness of collaborative care for the treatment of major depressive disorder in primary care. A systematic review. BMC Health Serv Res. 2010 Jan 19;10:19. Review.
Van Steenbergen-Weijenburg KM, de Vroege L, Ploeger RR, Brals JW, Vloedbeld MG, Veneman TF, Hakkaart-van Roijen L, Rutten FF, Beekman AT, van der Feltz-Cornelis CM. Validation of the PHQ-9 as a screening instrument for depression in diabetes patients in specialized outpatient clinics. BMC Health Services Research 2010, Aug 12;10:235.
Steenhoek A, Koopmanschap MA. Doelmatigheid dure medicijnen afwegen. Medisch Contact. 2010;35;1709-1711.
Steenhoek A, Koopmanschap MA, Franken MG, Rutten FFH. Nieuwe geneesmiddelen: niet goed, geld terug? Ned Tijdschr Geneeskd. 2010;154:A2042.
Stolk EA, Oppe M, Scalone L, Krabbe PF. Discrete choice modeling for the quantification of health states: the case of the EQ-5D. Value Health. 2010 Dec;13(8):1005-13. Epub 2010 Sep 3.
Tan SS, Van Gils CW, Franken MG, Hakkaart-van Roijen L, Uyl-de Groot CA. The unit costs of inpatient hospital days, outpatient visits and daycare treatments in the field of oncology and hematology. Value Health. 2010 Sep-Oct;13 (6): 712-9. Epub 2010 Jun 7.
Tan SS, van Ineveld BM, Redekop WK, Hakkaart-van Roijen L. Structural reforms and hospital payment in the Netherlands. EuroObserver. 2010 Autumn;12(3):7-9.
Tan SS, Van Linschoten RL, Van Middelkoop M, Koes BW, Bierma-Zeinstra SM, Koopmanschap MA. Cost-utility of exercise therapy in adolescents and young adults suffering from the patellofemoral pain syndrome. Scand J Med Sci Sports. 2010 Aug;20(4):568-79.
Tan SS, Rutten FFH, Hakkaart-van Roijen L. Incorporation of economic evidence in the Dutch guideline 'cardiovascular risk management'. Journal of Evaluation in Clinical Practice. doi:10.1111/j.1365-2753.2010.01481.x.
Tsiachristas A, Hipple-Walters B, Lemmens KM, Nieboer AP, Rutten-van Mölken MP. Towards integrated care for chronic conditions: Dutch policy developments to overcome the (financial) barriers. Health Policy. 2010 Nov 8. [Epub ahead of print]
Uyl-de Groot CA, de Groot S, Steenhoek A. The economics of improved cancer survival rates: better outcomes, higher costs. Expert Rev Pharmacoecon Outcomes Res. 2010 Jun;10(3):283-92.
Uyl-de Groot CA, Senft A, De Bree R, Leemans CR, Hoekstra OS. Chest CT and whole-body 18F-FDG PET are cost-effective in screening for distant metastases in head and neck cancer patients. J Nucl Med 2010; 51: 176-182.
Vemer P, Rutten-van Mölken MPMH. Crossing borders: factors affecting differences in cost-effectiveness of smoking cessation interventions between European countries. Value Health 2010; 13: 230-241.
Vemer P, Rutten-van Mölken MP. Largely ignored: the impact of the threshold value for a QALY
on the importance of a transferability factor. Eur J Health Econ. 2010 May 30. [Epub ahead of print]
Verhoef TI, Redekop WK, Darba J, Geitona M, Hughes DA, Siebert U, de Boer A, Maitland-van der Zee AH, Barallon R, Briz M, Daly A, Haschke-Becher E, Kamali F, Kirchheiner J, Manolopoulos VG, Pirmohamed M, Rosendaal FR, van Schie RM, Wadelius M; EU-PACT Group. A systematic review of cost-effectiveness analyses of pharmacogenetic-guided dosing in treatment with coumarin derivatives. Pharmacogenomics. 2010 Jul;11(7):989-1002.
Verhoef TI, Schalekamp T, Redekop WK, de Boer A, Maitland-van der Zee AH. Clinical and economic consequences of pharmacogenetic-guided dosing of warfarin. Expert Rev Pharmacoecon Outcomes Res. 2010 Aug;10(4):375-8.
Vermaire JH, Hoogstraten J, van Loveren C, Poorterman JH, van Exel NJ. Attitudes towards oral health among parents of 6-year-old children at risk of developing caries. Community Dent Oral Epidemiol. 2010 Jul 19. [Epub ahead of print].
Versteegh MM, Rowen D, Brazier JE, Stolk EA. Mapping onto EQ-5D for patients in poor health. Health Qual Life Outcomes. 2010 Nov 26;8(1):141.
Van Vollenhoven RF, Severens JL. Observational studies: a valuable source for data on the true value of RA therapies. Clin Rheumatol. 2011 Mar;30 Suppl 1:S19-24. Epub 2010 Dec 22.
Van Wetering EJ, Van Exel NJA, Brouwer WBF. Piecing the jigsaw puzzle of adolescent happiness. Journal of Economic Psychology 31 (2010) 923–935.
Van Wetering CR, Hoogendoorn M, Mol SJ, Rutten-van Mölken MPMH, Schols AM. Short- and long-term efficacy of a community-based COPD management programme in less advanced COPD: a randomised controlled trial. Thorax 2010; 65: 7-13.
Van Wetering CR, Hoogendoorn M, Broekhuizen R, Geraerts-Keeris GJ, De Munck DR, Rutten-van Mölken MP, Schols AM. Efficacy and costs of nutritional rehabilitation in muscle-wasted patients with chronic obstructive pulmonary disease in a community-based setting: a prespecified subgroup analysis of the INTERCOM trial. J Am Med Dir Assoc. 2010 Mar;11(3):179-87. Epub 2010 Feb 4.
Wolleswinkel-van den Bosch JH, Stolk EA, Francois M, Gasparini R, Brosa M. The health care burden and societal impact of acute otitis media in seven European countries: results of an Internet survey. Vaccine. 2010 Nov 19;28 Suppl 6:G39-52.
Wong A, Van Baal PHM, Boshuizen HC, Polder JJ. Exploring the influence of proximity to death on disease-specific hospital expenditures: a carpaccio of red herrings. Health Econ 2010 Mar 15.
Wong A, Elderkamp-de Groot R, Polder J, van Exel J. Predictors of long-term care utilization by Dutch hospital patients aged 65+. BMC Health Serv Res. 2010 May 6;10:110.
Wyers CE, Breedveld-Peters JJ, Reijven PL, van Helden S, Guldemond NA, Severens JL, Verburg AD, Meesters B, van Rhijn LW, Dagnelie PC. Efficacy and cost-effectiveness of nutritional intervention in elderly after hip fracture: design of a randomized controlled trial. BMC Public Health. 2010 Apr 27;10:212.
2009
Attema AE. De TTO-methode en correctie voor tijdsvoorkeur. VGE Bulletin 2009; 26: 14-17.
Attema AE, Brouwer WBF. The correction of TTO-scores for utility curvature using a risk-free utility elicitation method. J Health Econ 2009; 28: 234-243.
Bago d'Uva T, Jones AM, Van Doorslaer EKA. Measurement of horizontal inequity in health care utilisation using European panel data. J Health Econ 2009; 28: 280-289.
Beeh KM, Hederer B, Glaab T, Müller A, Rutten-van Mölken MPMH, Kesten S, Vogelmeier C. Study design considerations in a large COPD trial comparing effects of tiotropium with salmeterol on exacerbations. Int J Chron Obstruct Pulmon Dis 2009; 4: 119-125.
Bijlenga D, Birnie E, Bonsel GJ. Feasibility, reliability, and validity of three health-state valuation methods using multiple-outcome vignettes on moderate-risk pregnancy at term. Value Health 2009; 12: 821-827.
Boormans EM, Birnie E, Bilardo CM, Oepkes D, Bonsel GJ, Van Lith JM. Karyotyping or rapid aneuploidy detection in prenatal diagnosis? The different views of users and providers of prenatal care. BJOG 2009; 116: 1396-1399.
Boot CR, Van Exel NJA, Van der Gulden JW. "My lung disease won't go away, it's there to stay": profiles of adaptation to functional limitations in workers with asthma and COPD. J Occup Rehabil 2009; 19: 284-292.
Bouwmans CAM, Janssen J, Huijgens P, Uyl-de Groot CA. Costs of haematological adverse events in chronic myeloid leukaemia patients: a retrospective cost analysis of the treatment of anaemia, neutropenia and thrombocytopenia in patients with chronic myeloid leukaemia. J Med Econ 2009; 12: 164-169.
Brouwer WBF, Grootenboer S, Sendi P. The incorporation of income and leisure in health state valuations when the measure is silent: an empirical inquiry into the sound of silence. Med Decis Making 2009; 29: 503-512.
Christiaans I, Van Langen IM, Birnie E, Bonsel GJ, Wilde AA, Smets EM. Genetic counseling and cardiac care in predictively tested hypertrophic cardiomyopathy mutation carriers: the patients' perspective. Am J Med Genet A 2009; 149A: 1444-1451.
Christiaans I, Van Langen IM, Birnie E, Bonsel GJ, Wilde AA, Smets EM. Quality of life and psychological distress in hypertrophic cardiomyopathy mutation carriers: a cross-sectional cohort study. Am J Med Genet A 2009; 149A: 602-612.
Cramm JM, Finkenflügel H, Kuijsten R, Van Exel NJA. How employment support and social integration programmes are viewed by the intellectually disabled. J Intellect Disabil Res 2009; 53: 512-520.
Denktas S, Koopmans G, Birnie E, Foets M, Bonsel GJ. Ethnic background and differences in health care use: a national cross-sectional study of native Dutch and immigrant elderly in the Netherlands. Int J Equity Health 2009; 8: 35.
Drummond M, Barbieri M, Cook J, Glick H, Lis J, Malik F, Reed S, Rutten FFH, Sculpher M, Severens J. Transferability of economic evaluations across jurisdictions: ISPOR Good Research Practices Task Force report. Value Health 2009; 12: 409-418.
Goossens LMA, Riemersma RA, Postma DS, Van der Molen T, Rutten-van Mölken MPMH. An economic evaluation of budesonide/formoterol for maintenance and reliever treatment in asthma in general practice. Adv Ther 2009; 26: 872-885.
Goossens LMA, Standaert B, Hartwig N, Hövels AM, Al MJ. Conclusion on cost-effectiveness of rotavirus vaccination highly dependent on assumptions. Vaccine 2009; 27: 2531-2532.
Groenendijk AG, Birnie E, De Blok S, Adriaanse AH, Ankum WM, Roovers JP, Bonsel GJ. Clinical-decision taking in primary pelvic organ prolapse: the effects of diagnostic tests on treatment selection in comparison with a consensus meeting. Int Urogynecol J Pelvic Floor Dysfunct 2009; 20: 711-719.
Groenendijk AG, Birnie E, Boeckxstaens GE, Roovers JP, Bonsel GJ. Anorectal function testing and anal endosonography in the diagnostic work-up of patients with primary pelvic organ prolapse. Gynecol Obstet Invest 2009; 67: 187-194.
Hakkaart L, Verboom P, Phillips R, Al MJ. The cost utility of solifenacin in the treatment of overactive bladder. Int Urol Nephrol 2009; 41: 293-298.
Hoefman RJ, De Klerk MMY, Foets M. Het aanvragen van voorzieningen door personen met een lichamelijke beperking: belemmeringen en hulp van het sociale netwerk. TSG 2009; 87: 20-26.
Holland J, Van Exel NJA, Schut FT, Brouwer WBF. Some pain, no gain: experiences with the no-claim rebate in the Dutch health care system. Health Econ Policy Law 2009 Feb 25 [Epub ahead of print].
Hoogendoorn M, Van Wetering CR, Schols AM, Rutten-van Mölken MPMH. Is INTERdisicplinary COMmunity-based COPD management (INTERCOM) cost-effective? Eur Respir J 2009 Jul 2 [Epub ahead of print].
Hoogendoorn M, Van Wetering CR, Schols AM, Rutten-van Mölken MPMH. Self-report versus care provider registration of health care utilization: impact on cost and cost-utility. Int J Technol Assess Health Care 2009; 25: 588-595.
Van Hooren AC, Brouwer J, De Bree R, Hoekstra OS, Leemans CR, Uyl-de Groot CA. The cost-effectiveness of 18FDG-PET in selecting patients with suspicion of recurrent laryngeal carcinoma after radiotherapy for direct laryngoscopy. Eur Arch Otorhinolaryngol 2009; 266: 1441-1448.
Van Kippersluis H, Van Ourti T, O'Donnell O, Van Doorslaer EKA. Health and income across the life cycle and generations in Europe. J Health Econ 2009; 28: 818-830.
Krol M, Sendi P, Brouwer WBF. Breaking the silence: exploring the potential effects of explicit instructions on incorporating income and leisure in TTO exercises. Value Health 2009; 12: 172-180.
McGhan WF, Al MJ, Doshi JA, Kamae I, Marx SE, Rindress D. The ISPOR Good Practices for Quality Improvement of Cost-Effectiveness Research Task Force Report. Value Health 2009; 12: 1086-1099.
McGrail KM, Van Doorslaer EKA, Ross NA, Sanmartin C. Income-related health inequalities in Canada and the United States: a decomposition analysis. Am J Public Health 2009; 99: 1856-1863.
De Meijer CA, Koopmanschap MA, Koolman XH, Van Doorslaer EKA. The role of disability in explaining long-term care utilization. Med Care 2009; 47: 1156-1163.
Muntingh AD, Van der Feltz-Cornelis CM, Van Marwijk HW, Spinhoven P, Assendelft WJ, De Waal MW, Hakkaart-van Roijen L, Adèr HJ, Van Balkom AJ. Collaborative stepped care for anxiety disorders in primary care: aims and design of a randomized controlled trial. BMC Health Serv Res 2009; 9: 159.
Niazkhani Z, Van der Sijs H, Pirnejad H, Redekop WK, Aarts J. Same system, different outcomes: comparing the transitions from two paper-based systems to the same computerized physician order entry system. Int J Med Inform 2009; 78: 170-181.
Niëns LM, Brouwer WBF. Better measures of affordability required. Lancet 2009; 373: 1081-1082.
Niëns LM, Lowery D. Gendered epidemiology: sexual equality and the prevalence of HIV/AIDS in Sub-Saharan Africa. Soc Sci Q 2009; 90: 1134-1144.
Niezen MGH, De Bont A, Busschbach JJV, Cohen JP, Stolk EA. Finding legitimacy for the role of budget impact in drug reimbursement decisions. Int J Technol Assess Health Care 2009; 25: 49-55.
Van Nooten FE, Koolman X, Brouwer WBF. The influence of subjective life expectancy on health state valuations using a 10 year TTO. Health Econ 2009; 18: 549-558.
O'Donnell O, Nicolas Lopez A, Van Doorslaer EKA. Growing richer and taller: explaining change in the distribution of child nutritional status during Vietnam's economic boom. J Dev Econ 2009; 88: 45-58.
Van Ourti T, Van Doorslaer EKA, Koolman X. The effect of income growth and inequality on health inequality: theory and empirical evidence from the European Panel. J Health Econ 2009; 28: 525-539.
Van de Poel E, O'Donnell O, Van Doorslaer EKA. Urbanization and the spread of diseases of affluence in China. Econ Hum Biol 2009; 7: 200-216.
Van de Poel E, O'Donnell O, Van Doorslaer EKA. What explains the rural-urban gap in infant mortality: household or community characteristics? Demography 2009; 46: 827-850.
Poley MJ, Stolk EA, Brouwer WBF. The use and impact of HTA in decision making in the Netherlands. Euro Observer 2009; 11: 7-8.
Rappange DR, Van Baal PHM, Van Exel NJA, Feenstra TL, Rutten FFH, Brouwer WBF. I costi sanitari indiretti (non correlati) durante gli anni di vita guadagnati: devono essere inclusi nelle valutazioni economiche degli interventi sanitari? Pharmacoeconomics Italian Research Articles 2009; 11: 55-70.
Rappange DR, Brouwer WBF, Van Exel NJA. Back to the consideration of future consequences scale: time to reconsider? J Soc Psychol 2009; 149: 562-584.
Rappange DR, Brouwer WBF, Hoogenveen RT, Van Baal PHM. Healthcare costs and obesity prevention: drug costs and other sector-specific consequences. Pharmacoeconomics 2009; 27: 1031-1044.
Ringburg AN, Buljac M, Stolk EA, Van Lieshout EM, Van Beeck EF, Patka P, Schipper IB. Willingness to pay for lives saved by Helicopter Emergency Medical Services. Prehosp Emerg Care 2009; 13: 37-43.
Rutten FFH. Zicht op zorgpakketten in Europa: resultaten van het Health Basket project. Health Management Forum 2009; 1: 28-30.
Rutten FFH, Uyl-de Groot CA, Vulto AG. Innovative payment systems for medicines in Europe. Eur J Hosp Pharm Pract 2009; 15: 60-62.
Rutten-van Mölken MPMH. Raising the awareness: projecting the future burden of COPD with the BOLD model. Eur Respir J 2009; 34: 787-789.
Rutten-van Mölken MPMH, Hoogendoorn M, Lamers LM. Holistic preferences for 1-year health profiles describing fluctuations in health: the case of chronic obstructive pulmonary disease. Pharmacoeconomics 2009; 27: 465-477.
Van Schie RM, Wadelius MI, Kamali F, Daly AK, Manolopoulos VG, De Boer A, Barallon R, Verhoef TI, Kirchheiner J, Haschke-Becher E, Briz M, Rosendaal FR, Redekop WK, Pirmohamed M, Van der Zee AH. Genotype-guided dosing of coumarin derivatives: the European pharmacogenetics of anticoagulant therapy (EU-PACT) trial design. Pharmacogenomics 2009; 10: 1687-1695.
Smit F, Willemse G, Meulenbeek P, Koopmanschap MA, Van Balkom A, Spinhoven P, Cuijpers P. Preventing panic disorder: cost-effectiveness analysis alongside a pragmatic randomised trial. Cost Eff Resour Alloc 2009; 7: 8.
Stolk EA, De Bont A, Van Halteren AR, Bijlmer RJ, Poley MJ. Role of health technology assessment in shaping the benefits package in The Netherlands. Expert Rev Pharmacoecon Outcomes Res 2009; 9: 85-94.
Tan SS, Van Ineveld BM, Redekop WK, Hakkaart-van Roijen L. Comparing methodologies for the allocation of overhead and capital costs to hospital services. Value Health 2008 Nov 19 [Epub ahead of print].
Tan SS, Oppe M, Zoet-Nugteren SK, Niezen RA, Kofflard MJM, Ten Cate FJ, Hakkaart-van Roijen L. A microcosting study of diagnostic tests for the detection of coronary artery disease in the Netherlands. Eur J Radiol 2008 Aug 12 [Epub ahead of print].
Tan SS, Rutten FFH, Van Ineveld BM, Redekop WK, Hakkaart-van Roijen L. Comparing methodologies for the cost estimation of hospital services. Eur J Health Econ 2009; 10: 39-45.
Thunnissen MM, Duivenvoorden HJ, Busschbach JJV, Hakkaart-van Roijen L, Van Tilburg W, Verheul E, Trijsburg W. De effectiviteit van re-integratietraining versus boostersessies na kortdurende klinische psychotherapie: een gerandomiseerd klinisch onderzoek. Tijdschr Psychiatr 2009; 51: 75-86.
Uiters E, Devillé W, Foets M, Spreeuwenberg P, Groenewegen PP. Differences between immigrant and non-immigrant groups in the use of primary medical care: a systematic review. BMC Health Serv Res 2009; 9: 76.
Uyl-de Groot CA, Stupp R, Van der Bent M. Cost-effectiveness of temozolomide for the treatment of newly diagnosed glioblastoma multiforme. Expert Rev Pharmacoecon Outcomes Res 2009; 9: 235-241.
Vehmeijer JT, Christiaans I, Van Langen IM, Birnie E, Bonsel GJ, Smets EM, Wilde AA. Risk stratification for sudden cardiac death in hypertrophic cardiomyopathy: Dutch cardiologists and the care of mutation carriers. Neth Heart J 2009; 17: 464-469.
2008
Al MJ, Maniadakis N, Grijseels EWM, Janssen M. Costs and effects of various analgesic treatments for patients with rheumatoid arthritis and osteoarthritis in the Netherlands. Value Health 2008; 11: 589-599.
Attema AE. De rol van tijdsvoorkeur bij de waardering van gezondheid. TPEdigitaal 2008; 2: 92-105.
Attema AE, Brouwer WBF. Can we fix it? Yes we can! But what? A new test of procedural invariance in TTO-measurement. Health Econ 2008; 17: 877-885.
Van Baal PHM, Brouwer WBF, De Wit GA, Hoogenveen RT, Polder JJ. De invloed van roken en overgewicht op zorguitgaven. TSG 2008; 86: 150-155.
Van Baal PHM, Polder JJ, De Wit GA, Hoogenveen RT, Feenstra TL, Boshuizen HC, Engelfriet PM, Brouwer WBF. Lifetime medical costs of obesity: prevention no cure for increasing health expenditure. PLoS Med 2008; 5: e29.
Van den Berg B, Al MJ, Van Exel NJA, Koopmanschap MA, Brouwer WBF. Economic valuation of informal care: conjoint analysis applied in a heterogeneous population of informal caregivers. Value Health 2008; 11: 1041-1050.
Van den Bos T, Visser-Meily A, Van Exel NJA. De praktijkondersteuner meer in beeld in de zorg aan CVA-patiënten. Tijdschrift voor Praktijkondersteuning 2008; 3: 7-10.
Bouwmans CAM, Lintsen BAME, Al MJ, Verhaak CM, Eijkemans RJC, Habbema JDF, Braat DDM, Hakkaart-van Roijen L. Absence from work and emotional stress in women undergoing IVF or ICSI: an analysis of IVF-related absence from work in women and the contribution of general and emotional factors. Acta Obstet Gynecol Scand 2008; 87: 1169-1175.
Bouwmans CAM, Lintsen BME, Eijkemans MJC, Habbema JDF, Braat DDM, Hakkaart L. A detailed cost analysis of in vitro fertilization and intracytoplasmic sperm injection treatment. Fertil Steril 2008; 89: 331-341.
Breekveldt-Postma NS, Koerselman J, Erkens JA, Van der Molen T, Lammers JWJ, Herings RMC. Treatment with inhaled corticosteroids in asthma is too often discontinued. Pharmacoepidemiol Drug Saf 2008; 17: 411-422.
Brouwer WBF. Perspective, costs, outcomes and discounting in pharmacoeconomic evaluations. Eur J Hosp Pharm Pract 2008; 14: 20-22.
Brouwer WBF, Culyer AJ, Van Exel NJA, Rutten FFH. Welfarism vs. extra-welfarism. J Health Econ 2008; 27: 325-338.
Brouwer WBF, Van Exel NJA, Van Baal PHM. Kosten in gewonnen levensjaren niet langer negeren! TSG 2008; 86: 1-2.
Brouwer WBF, Van Exel NJA, Baker R, Donaldson C. The new myth: the social value of the QALY. Pharmacoeconomics 2008; 26: 1-4.
Brouwer WBF, Rutten FFH. Een kwaliteitsinstituut voor de zorg: liever vandaag dan morgen! VGE Infobulletin 2008; 25: 4-6.
Cazzola M, MacNee W, Martinez FJ, Rabe KF, Franciosi LG, Barnes PJ, Brusasco V, Burge PS, Calverley PM, Celli BR, Jones PW, Mahler DA, Make B, Miravitlles M, Page CP, Palange P, Parr D, Pistolesi M, Rennard SI, Rutten-van Mölken MPMH, Stockley R, Sullivan SD, Wedzicha JA, Wouters EF. Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J 2008; 31: 416-469.
Cohen JP, Stolk EA, Niezen MGH. Role of budget impact in drug reimbursement decisions. J Health Polit Policy Law 2008; 33: 225-247.
Delhaas EM, Beersen N, Redekop WK, Klazinga NS. Long-term outcomes of continuous intrathecal baclofen infusion for treatment of spasticity: a prospective multicenter follow-up study. Neuromodulation 2008; 11: 227-236.
Van Exel NJA, Bobinac A, Koopmanschap MA, Brouwer WBF. The invisible hands made visible: recognizing the value of informal care in healthcare decision-making. Exp Rev Pharmacoeconomics Outcomes Res 2008; 8: 557-561.
Van Exel NJA, De Graaf G, Brouwer WBF. Give me a break! Informal caregiver attitudes towards respite care. Health Policy 2008; 88: 73-87.
Van Exel NJA, De Ruiter M, Brouwer WBF. When time is not on your side: patient experiences with waiting for home care and admission to a nursing or residential home. Patient 2008; 1: 55-71.
Feenstra TL, Van Baal PHM, Gandjour A, Brouwer WBF. Future costs in economic evaluation: a comment on Lee. J Health Econ 2008; 27: 1645-1649.
Galani C, Al MJ, Schneider H, Rutten FFH. Uncertainty in decision-making: value of additional information in the cost-effectiveness of lifestyle intervention in overweight and obese people. Value Health 2008; 11: 424-434.
Galani C, Rutten FFH. Self-reported healthcare decision-makers' attitudes towards economic evaluations of medical technologies. Curr Med Res Opin 2008; 24: 3049-3058.
Gischler SJ, Mazer P, Poley MJ, Tibboel D, Van Dijk M. Telephone helpline for parents of children with congenital anomalies. J Adv Nurs 2008; 64: 625-631.
Goossens LMA, Standaert B, Hartwig N, Hövels AM, Al MJ. The cost-utility of rotavirus vaccination with Rotarix (RIX4414) in the Netherlands. Vaccine 2008; 26: 1118-1127.
Groenewoud AS, Van Exel NJA, Berg M, Huijsman R. Building quality report cards for geriatric care in The Netherlands: using concept mapping to identify the appropriate "building blocks" from the consumer's perspective. Gerontologist 2008; 48: 79-92.
Heijink R, Noethen M, Renaud T, Koopmanschap MA, Polder J. Cost of illness: an international comparison Australia, Canada, France, Germany and The Netherlands. Health Policy 2008; 88: 49-61.
Hoogendoorn M, Welsing P, Rutten-van Mölken MPMH. Cost-effectiveness of varenicline compared with bupropion, NRT, and nortriptyline for smoking cessation in the Netherlands. Curr Med Res Opin 2008; 24: 51-61.
Kerremans JJ, Verboom P, Stijnen T, Hakkaart-van Roijen L, Goessens W, Verbrugh HA, Vos MC. Rapid identification and antimicrobial susceptibility testing reduce antibiotic use and accelerate pathogen-directed antibiotic use. J Antimicrob Chemother 2008; 61: 428-435.
Koopmanschap MA, Van Exel NJA, Van den Berg B, Brouwer WBF. An overview of methods and applications to value informal care in economic evaluations of healthcare. Pharmacoeconomics 2008; 26: 269-280.
Koopmanschap MA, Van Exel NJA, Van den Berg B, Brouwer WBF. Una panoramica delle metodologie per la valutazione delle cure informali negli studi di economia sanitaria. Pharmacoeconomics Italian Research Articles 2008; 10: 99-111.
Kreuger L, Van Exel NJA, Nieboer A. Needs of persons with severe intellectual disabilities: a Q-methodological study of clients with severe behavioural disorders and severe intellectual disabilities. J Appl Res Intellect Disabil 2008; 21: 466-476.
Kuijsten R, Cramm JM, Van Exel NJA, Finkenflügel H. Werkt werken? Een Q-methodologisch onderzoek naar de mening van mensen met een verstandelijke beperking over de bijdrage van individueel begeleid werken aan hun sociale integratie. Nederlands Tijdschrift voor de Zorg aan mensen met verstandelijke beperkingen (NTZ) 2008; 34: 34-46.
Lamers LM, Stupp R, Van den Bent MJ, Al MJ, Gorlia T, Wasserfallen JB, Mittmann N, Jin Seung S, Crott R, Uyl-de Groot CA. Cost-effectiveness of temozolomide for the treatment of newly diagnosed glioblastoma multiforme: a report from the EORTC 26981/22981 NCI-C CE3 Intergroup Study. Cancer 2008; 112: 1337-1344.
Nijdam WM, Levendag PC, Noever I, Schmitz PI, Uyl-de Groot CA. Longitudinal changes in quality of life and costs in long-term survivors of tumors of the oropharynx treated with brachytherapy or surgery. Brachytherapy 2008; 7: 343-350.
Oostenbrink JB, Al MJ, Oppe M, Rutten-van Mölken MPMH. Expected value of perfect information: an empirical example of reducing decision uncertainty by conducting additional research. Value Health 2008; 11: 1070-1080.
Polder JJ, Brouwer WBF. Rechtvaardige verdeling: het verhaal van Bart, Johan, Werner en Kees. Tien woorden gezondheidseconomie (4). TSG 2008; 86: 63-68.
Poley MJ, Brouwer WBF, Busschbach JJV, Hazebroek FWJ, Tibboel D, Rutten FFH, Molenaar JC. Cost-effectiveness of neonatal surgery: first greeted with scepticism, now increasingly accepted. Pediatr Surg Int 2008; 24: 119-127.
Rappange DR, Van Baal PH, Van Exel NJA, Feenstra TL, Rutten FFH, Brouwer WBF. Unrelated medical costs in life-years gained: should they be included in economic evaluations of healthcare interventions? Pharmacoeconomics 2008; 26: 815-830.
Redekop WK, Orlewska E, Maciejewski P, Rutten FFH, Niessen LW. Costs and effects of secondary prevention with perindopril in stable coronary heart disease in Poland: an analysis of the EUROPA study including 1251 Polish patients. Pharmacoeconomics 2008; 26: 861-877.
Rutten FFH, Vulto AG. Pharmacoeconomics: science, practice and challenges. Eur J Hosp Pharm Pract 2008; 14: 16.
Scalone L, Mantovani LG, Krol M, Rofail D, Ravera S, Bisconte MG, Borgna-Pignatti C, Borsellino Z, Cianciulli P, Gallisai D, Prossomariti L, Stefàno I, Cappellini MD. Costs, quality of life, treatment satisfaction and compliance in patients with beta-thalassemia major undergoing iron chelation therapy: the ITHACA study. Curr Med Res Opin 2008; 24: 1905-1917.
Steenhoek A, Uyl-de Groot CA, Rutten FFH. Uitkomstenonderzoek: hoogste tijd voor een definitie! TSG 2008; 86: 18-21.
Tan SS, Hakkaart-van Roijen L, Al MJ, Bouwmans CAM, Hoogendoorn ME, Spronk PE, Bakker J. A microcosting study of intensive care unit stay in the Netherlands. J Intensive Care Med 2008; 23: 250-257.
Tan SS, Redekop WK, Rutten FFH. Costs and prices of single dental fillings in Europe: a micro-costing study. Health Econ 2008; 17: S83-S93.
Tielen M, Van Staa AL, Jedeloo S, Van Exel NJA, Weimar W. Q-methodology to identify young adult renal transplant recipients at risk for nonadherence. Transplantation 2008; 85: 700-706.
Utens CMA, Goossens LMA, Smeenk FWJM, van Schayck OCP, van Litsenburg W, Janssen A, van Vliet M, Seezink W, Demunck DRAJ, van de Pas B, de Bruijn PJ, van der Pouw A, Retera JMAM, de Laat-Bierings P, van Eijsden L, Braken M, Eijsermans R, Rutten-van Molken MPMH. Effectiveness and cost-effectiveness of early assisted discharge for Chronic Obstructive Pulmonary Disease exacerbations: the design of a randomised controlled trial. BMC Public Health 2010, 10:618
Van Wetering CR, Van Nooten FE, Mol SJM, Hoogendoorn M, Rutten-van Mölken MPMH, Schols AM. Systemic impairment in relation to disease burden in patients with moderate COPD eligible for a lifestyle program: findings from the INTERCOM trial. Int J Chron Obstruct Pulmon Dis 2008; 3: 443-451.
2007
Agyemang C, Bhopal R, Redekop WK. Does the pulse pressure in people of European, African and South Asian descent differ? A systematic review and meta-analysis of UK data. J Hum Hypertens 2007; 21: 598-609.
Van Baal PHM, Brouwer WBF, Hoogenveen RT, Feenstra TL. Increasing tobacco taxes: a cheap tool to increase public health. Health Policy 2007; 82: 142-152.
Van Baal PHM, Feenstra TL, Hoogenveen RT, De Wit GA, Brouwer WBF. Unrelated medical care in life years gained and the cost utility of primary prevention: in search of a 'perfect' cost-utility ratio. Health Econ 2007; 16: 421-433.
Baltussen R, Ten Asbroek AH, Koolman X, Shrestha N, Bhattarai P, Niessen LW. Priority setting using multiple criteria: should a lung health programme be implemented in Nepal? Health Policy Plan 2007; 22: 178-185.
De Bont A, Zandwijken G, Stolk EA, Niessen LW. Prioritisation by physicians in the Netherlands: the growth hormone example in drug reimbursement decisions. Health Policy 2007; 80: 369-377.
Van den Bos GAM, Visser-Meily JMA, Van Exel NJA. Optimalisering van de zorg aan CVA-patiënten in de huisartsenpraktijk. Huisarts & Wetenschap 2007; 50: 552-556.
De Bree R, Van der Putten L, Hoekstra OS, Kuik DJ, Uyl-de Groot CA, Van Tinteren H, Leemans CR, Boers M. A randomized trial of PET scanning to improve diagnostic yield of direct laryngoscopy in patients with suspicion of recurrent laryngeal carcinoma after radiotherapy. Contemp Clin Trials 2007; 28: 705-712.
De Bree R, Reith R, Quak JJ, Uyl-de Groot CA, Van Agthoven M, Leemans CR. Free radial forearm flap versus pectoralis major myocutaneous flap reconstruction of oral and oropharyngeal defects: a cost analysis. Clin Otolaryngol 2007; 32: 275-282.
Brouwer WBF, Van Exel NJA, Van Baal PHM. De kosten in gewonnen levensjaren: tijd voor een nieuwe richtlijn! VGE Infobulletin 2007; 24: 11-14.
Brouwer WBF, Van Exel NJA, Van Baal PHM, Polder JJ. Economics and public health: engaged to be happily married! Eur J Public Health 2007; 17: 122-123.
Cohen JP. The new Dutch health insurance system and its implications for pharmaceutical innovation. Int J Pharm Healthcare Marketing 2007; 1: 214-225.
Cohen JP, Faden L, Predaris S, Young B. Patient access to pharmaceuticals: an international comparison. Eur J Health Econ 2007; 8: 253-266.
Cohen JP, Paquette C, Cairns C. Can Medicare draw lessons from Dutch experience with a national formulary. Drug Inf J; 2007; 41: 257-272.
Cohen JP, Stolk EA, Niezen MGH. The increasingly complex fourth hurdle for pharmaceuticals. Pharmacoeconomics 2007; 25: 727-734.
Cuijpers P, Smit F, Oostenbrink JB, De Graaf R, Ten Have M, Beekman A. Economic costs of minor depression: a population-based study. Acta Psychiatr Scand 2007; 115: 229-236.
Essink-Bot ML, Stuifbergen MC, Meerding WJ, Looman CW, Bonsel GJ for the VOTE group (incl WBF Brouwer). Individual differences in the use of the response scale determine valuations of hypothetical health states: an empirical study. BMC Health Serv Res 2007; 7: 62.
Van Exel NJA, Bobinac A, Koopmanschap MA, Brouwer WBF. Providing informal care: a burden and a blessing. Health and Ageing (Newsletter of the Geneva Association of Risk & Insurance Economics) 2007; 16: 10-13.
Van Exel NJA, De Graaf G, Brouwer WBF. Care for a break? An investigation of informal caregivers' attitudes toward respite care using Q-methodology. Health Policy 2007; 83: 332-342.
Galani C, Schneider H, Rutten FFH. Modelling the lifetime costs and health effects of lifestyle intervention in the prevention and treatment of obesity in Switzerland. Int J Public Health 2007; 52: 1-11.
Goor KM, Peeters AJGE, Mahieu HF, Langendijk JA, Leemans CR, Verdonck-de Leeuw IM, Van Agthoven M. Cordectomy by CO(2) laser or radiotherapy for small T1a glottic carcinomas: costs, local control, survival, quality of life, and voice quality. Head Neck 2007; 29: 128-136.
Goossensen A, Zijlstra P, Koopmanschap MA. Measuring shared decision making processes in psychiatry: skills versus patient satisfaction. Patient Educ Couns 2007; 67: 50-56.
Gravelle H, Brouwer WBF, Niessen LW, Postma M, Rutten FFH. Discounting in economic evaluations: stepping forward towards optimal decision rules. Health Econ 2007; 16: 307-317.
Hakkaart-van Roijen L, Lamers LM, Bouwmans CAM, Van Straten A, Donker MCH. Comparison of EQ-5D and SF-6D in mental health patients. J Ment Health Policy Econ 2007; 10: S17.
Hakkaart-van Roijen L, Zwirs BW, Bouwmans CAM, Tan SS, Schulpen TW, Vlasveld L, Buitelaar JK. Societal costs and quality of life of children suffering from attention deficient hyperactivity disorder (ADHD). Eur Child Adolesc Psychiatry 2007; 16: 316-326.
Hart HE, Redekop WK, Bilo HJG, Meyboom-de Jong B, Berg M. Health related quality of life in patients with type I diabetes mellitus: generic & disease-specific measurement. Indian J Med Res 2007; 125: 203-216.
Horn EK, Van Benthem TB, Hakkaart-van Roijen L, Van Marwijk HW, Beekman AT, Rutten FFH, Van der Feltz-Cornelis CM. Cost-effectiveness of collaborative care for chronically ill patients with comorbid depressive disorder in the general hospital setting, a randomised controlled trial. BMC Health Serv Res 2007; 7: 28.
IJff MA, Huijbregts KM, Van Marwijk HW, Beekman AT, Hakkaart-van Roijen L, Rutten FFH, Unützer J, Van der Feltz-Cornelis CM. Cost-effectiveness of collaborative care including PST and an antidepressant treatment algorithm for the treatment of major depressive disorder in primary care; a randomised clinical trial. BMC Health Serv Res 2007; 7: 34.
Jansen E, Baltussen R, Van Doorslaer E, Ngirwamungu E, Nguyen MP, Kilima PM. An eye for inequality: how trachoma relates to poverty in Tanzania and Vietnam. Ophthalmic Epidemiol 2007; 14: 278-287.
Koopmanschap MA, Steenhoek A. Groter gebruik: lagere prijs. Kosten voor dure medicijnen rijzen de pan uit. Pharmaceutisch Weekblad 2007; 142: 21.
Krol M, Koopman M, Uyl-de Groot C, Punt CJA. A systematic review of economic analyses of pharmaceutical therapies for advanced colorectal cancer. Expert Opin Pharmacother 2007; 8: 1313-1328.
Lai T, Habicht J, Reinap M, Chisholm D, Baltussen R. Costs, health effects and cost-effectiveness of alcohol and tobacco control strategies in Estonia. Health Policy 2007; 84: 75-88.
Lamers LM. The transformation of utilities for health states worse than death: consequences for the estimation of EQ-5D value sets. Med Care 2007; 45: 238-244.
Lamers LM, Uyl-de Groot CA, Buijt I. The use of disease-specific outcome measures in cost-utility analysis: the development of Dutch societal preference weights for the FACT-L scale. Pharmacoeconomics 2007; 25: 591-603.
Lintsen AME, Eijkemans MJC, Hunault CC, Bouwmans CAM, Hakkaart L, Habbema JDF, Braat DDM. Predicting ongoing pregnancy chances after IVF and ICSI: a national prospective study. Hum Reprod 2007; 22: 2455-2462.
Luijsterburg PA, Lamers LM, Verhagen AP, Ostelo RW, Van den Hoogen HJ, Peul WC, Avezaat CJ, Koes BW. Cost-effectiveness of physical therapy and general practitioner care for sciatica. Spine 2007; 32: 1942-1948.
Niessen LW, Grijseels EWM, Koopmanschap MA, Rutten FFH. Economic analysis for clinical practice: the case of 31 national consensus guidelines in the Netherlands. J Eval Clin Pract 2007; 13: 68-78.
Niezen MGH, De Bont A, Stolk EA, Eyck A, Niessen LW, Stoevelaar HJ. Conditional reimbursement within the Dutch drug policy. Health Policy 2007; 84: 39-50.
Nijdam W, Levendag P, Fuller D, Schulz R, Prevost JB, Noever I, Uyl-de Groot CA. Robotic radiosurgery vs. brachytherapy as a boost to intensity modulated radiotherapy for tonsillar fossa and soft palate tumors: the clinical and economic impact of an emerging technology. Technol Cancer Res Treat 2007; 6: 611-620.
Polder JJ, Brouwer WBF. Een mistroostige wetenschap? TSG 2007; 85: 202-204.
Poley MJ, Edelenbos KI, Mosseveld M, Van Wijk MAM, De Bakker DH, Van der Lei J, Rutten-van Mölken MPMH. Cost consequences of implementing an electronic decision support system for ordering laboratory tests in primary care: evidence from a controlled prospective study in The Netherlands. Clin Chem 2007; 53: 213-219.
Rutten FFH, Brouwer WBF. Value for money in de zorg: geen woorden maar daden! M&O 2007: 171-179.
Rutten-van Mölken MPMH, Van Nooten FE, Lindemann M, Caeser M, Calverley PMA. A 1-year prospective cost-effectiveness analysis of roflumilast for the treatment of patients with severe chronic obstructive pulmonary disease. Pharmacoeconomics 2007; 25: 695-711.
Rutten-van Mölken MPMH, Oostenbrink JB, Miravitlles M, Monz BU. Modelling the 5-year cost effectiveness of tiotropium, salmeterol and ipratropium for the treatment of chronic obstructive pulmonary disease in Spain. Eur J Health Econ 2007; 8: 123-135.
Schandler M, Schwarz O, Hakkaart-van Roijen L, Jensen PS, Person U, Santosh P, Trott GE. Cost-effectiveness of ADHD treatment strategies in the international context: impact of therapeutic objective and comobidity. J Ment Health Policy Econ 2007; 10: S37.
Schandler M, Schwarz O, Hakkaart-van Roijen L, Jensen PS, Person U, Santosh P, Trott GE. Improving functional impairment in major life activities: cost-effectiveness of ADHD treatment strategies in the international context. J Ment Health Policy Econ 2007; 10: S38.
Sendi P, Brouwer WBF, Bucher HC, Weber R, Battegay M. When time is more than money: the allocation of time between work and leisure in HIV-infected patients. Soc Sci Med 2007; 64: 2355-2361.
Soeteman DI, Hakkaart-van Roijen L, Verheul R, Busschbach JJV. The economic burden of personality disorders. J Ment Health Policy Econ 2007; 10: S42.
Stalmeier PF, Lamers LM, Busschbach JJV, Krabbe PF. On the assessment of preferences for health and duration: maximal endurable time and better than dead preferences. Med Care 2007; 45: 835-841.
Steinbusch PJM, Oostenbrink JB, Zuurbier JJ, Schaepkens FJM. The risk of upcoding in casemix systems: a comparative study. Health Policy 2007; 81: 289-299.
Tan SS, Uyl-de Groot CA, Huijgens PC, Fibbe WE. Stem cell transplantation in Europe: trends and prospects. Eur J Cancer 2007; 43: 2359-2365.
2006
Van Agthoven M, Heule-Dieleman HA, Knegt PP, Kaanders JH, Baatenburg de Jong RJ, Kremer B, Rene Leemans C, Marres HA, Manni JJ, Langendijk JA, Levendag PC, Tjho-Heslinga RE, De Jong JM, De Boer MF, Uyl-de Groot CA. Compliance and efficiency before and after implementation of a clinical practice guideline for laryngeal carcinomas. Eur Arch Otorhinolaryngol 2006; 263: 729-737.
Anderson BO, Yip CH, Ramsey SD, Bengoa R, Braun S, Fitch M, Groot M, Sancho-Garnier H, Tsu VD; for the Global Summit Health Care Systems and Public Policy Panel. Breast cancer in limited-resource countries: health care systems and public policy. Breast J 2006; 12 Suppl 1: S54-69.
Baltussen R. Priority setting of public spending in developing countries: do not try to do everything for everybody. Health Policy 2006; 78: 149-156.
Baltussen R, Bruce E, Rhodes G, Narh-Bana SA, Agyepong I. Management of mutual health organizations in Ghana. Trop Med Int Health 2006; 11: 654-659.
Baltussen R, Niessen LW. Priority setting of health interventions: the need for multi-criteria decision analysis. Cost Eff Resour Alloc 2006; 4: 14.
Baltussen R, Stolk EA, Chisholm D, Aikins M. Towards a multi-criteria approach for priority setting: an application to Ghana. Health Econ 2006; 15: 689-696.
Baltussen R, Ye Y. Quality of care of modern health services as perceived by users and non-users in Burkina Faso. Int J Qual Health Care 2006; 18: 30-34.
Van den Berg B, Brouwer WBF, Van Exel NJA, Koopmanschap MA, Van den Bos GAM, Rutten FFH. Economic valuation of informal care: lessons from the application of the opportunity costs and proxy good methods. Soc Sci Med 2006; 62: 835-845.
Bleichrodt H, Van Doorslaer E. A welfare economics foundation for health inequality measurement. J Health Econ 2006; 25: 945-957.
Bleichrodt H, Eeckhoudt L. Willingness to pay for reductions in health risks when probabilities are distorted. Health Econ 2006; 15: 211-214.
Boersma C, Radeva JI, Koopmanschap MA, Voors AA, Postma MJ. Economic evaluation of valsartan in patients with chronic heart failure: results from Val-HeFT adapted to the Netherlands. J Med Econ 2006; 9: 121-131.
Boot HJ, De Melker HE, Stolk EA, De Wit GA, Kimman TG. Assessing the introduction of universal varicella vaccination in the Netherlands. Vaccine 2006; 24: 6288-6299.
Brouwer WBF. Too important to ignore: informal caregivers and other significant others. Pharmacoeconomics 2006; 24: 39-41.
Brouwer WBF, Van Baal PHM, Van Exel NJA. De dubbele prijs van succes: the pain is in the gain. TSG 2006; 84(Bijlage Economie en Volksgezondheid): 7-10.
Brouwer WBF, Calkoen P. Kiezen in de zorg moeilijk maar noodzakelijk. Ned Tijdschr Mondhygiëne 2006; 11: 18-21.
Brouwer WBF, Van Exel NJA, Baltussen RMPM, Rutten FFH. A dollar is a dollar is a dollar - or is it? Value Health 2006; 9: 341-347.
Brouwer WBF, Van Exel NJA, Van Gorp B, Redekop WK. The CarerQol instrument: a new instrument to measure care-related quality of life of informal caregivers for use in economic evaluations. Qual Life Res 2006; 15: 1005-1021.
Brouwer WBF, Van Exel NJA, Schut FT. De markt is geen zorg! TSG 2006; 84: 193-194.
Brouwer WBF, Polder JJ, Van Exel NJA, Van Baal P. Gezond leven niet per se goedkoper. Medisch Contact 2006; 61: 878-881.
Brouwer WBF, Polder JJ, Van Lienden H, Boot JM. Economie is goed voor volksgezondheid en zorg! TSG 2006; 84(Bijlage Economie en Volksgezondheid): 3.
Cohen JP. Cost-effectiveness and resource allocation [letter]. JAMA 2006; 295: 2723.
Cohen JP. Transatlantic convergence with respect to the fourth hurdle? Pharmacoeconomics 2006; 24 Suppl 2: 85-92.
Cohen JP, Cabanilla L, Sosnov J. Role of follow-on drugs and indications on the WHO Essential Drug List. J Clin Pharm Ther 2006; 31: 585-592.
Cohen JP, Cairns C, Paquette C, Faden L. Comparing patient access to pharmaceuticals in the UK and US. Appl Health Econ Health Policy 2006; 5: 177-187.
Dijkers M, Korving K, Van Exel NJA. Wat vindt de huisarts belangrijk tijdens een dienst? Een exploratief onderzoek naar de visie van huisartsen op de kwaliteit van huisartsenposten. Huisarts & Wetenschap 2006; 49: 447-453.
Dijkstra RF, Niessen LW, Braspenning JC, Adang E, Grol RT. Patient-centred and professional-directed implementation strategies for diabetic guidelines: a cluster-randomized trialbased cost-effectiveness analysis. Diabet Med 2006; 23: 164-170.
Van Etten G, Baltussen R, Bijlmakers L, Niessen LW. Advancing the Mexico agenda for health systems research: from clinical efficacy to population health. Trop Med Int Health 2006; 11: 1145-1146.
Van Exel NJA, Brouwer WBF, Van den Berg B, Koopmanschap MA. With a little help from an anchor: discussion and evidence of anchoring effects in contingent valuation. J Socio-Economics 2006; 35: 836-853.
Van Exel NJA, De Graaf G, Brouwer WBF. "Everyone dies, so you might as well have fun!" Attitudes of Dutch youths about their health lifestyle. Soc Sci Med 2006; 63: 2628-2639.
Van Exel NJA, Koopmanschap MA, McDonnell J, Chapple CR, Berges R, Rutten FFH. Medical consumption and costs during a one-year follow- up of patients with LUTS suggestive of BPH in six European countries: report of the TRIUMPH study. Eur Urol 2006; 49: 92-102.
Van Exel NJA, Morée M, Koopmanschap MA, Schreuder-Goedheijt T, Brouwer WBF. Respijtzorg: een verkenning van behoefte en gebruik onder 273 mantelzorgers. TSG 2006; 84: 90-99.
Van Exel NJA, Morée M, Koopmanschap MA, Schreuder-Goedheijt T, Brouwer WBF. Respite care: an explorative study of demand and use in Dutch informal caregivers. Health Policy 2006; 78: 194-208.
De Graaf G, Brouwer WBF, Van Exel NJA. Gezondheidshoudingen van jongeren in klas 1 en 2 van het voortgezet onderwijs: een Q-methodologische studie. TSG 2006; 84: 215-222.
Groot MT, Baltussen R, Uyl-de Groot CA, Anderson BO, Hortobagyi GN. Costs and health effects of breast cancer interventions in epidemiologically different regions of Africa, north america, and Asia. Breast J 2006; 12 Suppl 1: S81-90.
Groot MT, Huijgens PC, Uyl-de Groot CA. Introduction of expensive pharmaceuticals in haematooncology in the Netherlands and throughout Europe. Eur J Hosp Pharm Pract 2006; 12: 30-36.
Groot MT, Ossenkoppele GJ, Reed SD, Huijgens PC, Uyl-de Groot CA. Kosten-effectiviteit van de behandeling van chronisch myeloïde leukemie in het Imatinib tijdperk. Ned Tijdschr Hematol 2006; 3: 93-103.
Hakkaart-van Roijen L, Van Straten A, Al M, Rutten FFH, Donker M. Cost-utility of brief psychological treatment for depression and anxiety. Br J Psychiatry 2006; 188: 323-329.
Herder GJ, Kramer H, Hoekstra OS, Smit EF, Pruim J, Van Tinteren H, Comans EF, Verboom P, Uyl-de Groot CA, Welling A, Paul MA, Boers M, Postmus PE, Teule GJ, Groen HJ. Traditional versus up-front [18F] fluorodeoxyglucose-positron emission tomography staging of non-small-cell lung cancer: a Dutch cooperative randomized study. J Clin Oncol 2006; 24: 1800-1806.
Hoogendoorn M, Feenstra TL, Rutten-van Mölken MPMH. Toekomstprojecties van het zorggebruik en de kosten van astma en COPD in Nederland. Ned Tijdschr Geneeskd 2006; 150: 1243-1250.
Hoogendoorn M, Feenstra TL, Schermer TRJ, Hesselink AE, Rutten-van Mölken MPMH. Severity distribution of chronic obstructive pulmonary disease (COPD) in Dutch general practice. Resp Med 2006; 100: 83-86.
Hoogendoorn M, Rutten-van Mölken MPMH, Feenstra TL. Author reply to comments on 'A dynamic population model of disease progression in COPD'. Eur Respir J 2006; 27: 241-242.
Van Ineveld BM, Dohmen P, Redekop WK. De startende marktwerking in de gezondheidszorg. ESB 2006; 91: 470-473.
Kamphuis S, Nieboer A, Van Exel NJA. De slag om de verzekerde: concurrentie speelt ondergeschikte rol bij samenstelling aanvullende pakket. Medisch Contact 2006; 61: 143-145.
Van Kemenade YW, Brouwer WBF. Lang verwacht en toch gekomen: de stelselherzienning! ZM Magazine 2006; 22: 6-9.
Korthals-de Bos IBC, Gerritsen AAM, Van Tulder MW, Rutten-van Mölken MPMH, Ader HJ, De Vet HCW, Bouter LM. Surgery is more cost-effective than splinting for carpal tunnel syndrome in the Netherlands: results of an economic evaluation alongside a randomized controlled trial. BMC Musculoskelet Disord 2006; 7: 86.
Krol M, Brouwer WBF, Sendi P. Productivity costs in health-state valuations: does explicit instruction matter? Pharmacoeconomics 2006; 24: 401-414.
Lamers LM, Bouwmans CAM, Van Straten A, Donker MCH, Hakkaart-van Roijen L. Comparison of EQ-5D and SF-6D utilities in mental health patients. Health Econ 2006; 15: 1229-1236.
Lamers LM, McDonnell J, Stalmeier PFM, Krabbe PFM, Busschbach JJV. The Dutch tariff: results and arguments for an effective design for national EQ-5D valuation studies. Health Econ 2006; 15: 1121-1132.
Lamers LM, Stalmeier PFM, Krabbe PFM, Busschbach JJV. Inconsistencies in TTO and VAS values for EQ-5D health states. Med Decis Making 2006; 26: 173-181.
Van der Maas ICS, Brouwer WBF, Van Exel NJA. Zorg in eigen regie, of liever niet? Houdingen onder mensen van 55 jaar en ouder ten aanzien van het PgB als alternatief voor zorg in natura. TSG 2006; 84: 394-402.
Niezen MGH, Stolk EA, Steenhoek A, Uyl-de Groot CA. Inequalities in oncology care: economic consequences of high cost drugs. Eur J Cancer 2006; 42: 2887-2892.
Van Nooten F, Van Agthoven M. DBC's: visies en verwachtingen van het veld. ZM Magazine 2006; 22: 10-13.
Nuijten MJC, Poulsen Nautrup B, Liedgens H. Oral fixed drug combination analgesic tramadol/paracetamol: benefits for patients and budgets. Expert Rev Pharmacoeconomics Outcomes Res 2006; 6: 113-121.
Oostenbrink JB, Rutten FFH. Cost assessment and price setting of inpatient care in the Netherlands: the DBC case-mix system. Health Care Manag Sci 2006; 9: 287-294.
Redekop WK. Cost-effectiveness analyses of diagnostic strategies: a literature survey using the NHS Economic Evaluation Database. Expert Rev Pharmacoeconomics Outcomes Res 2006; 6: 41-48.
Rutten-van Mölken MPMH, Lee TA. Economic modeling in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2006; 3: 630-634.
Rutten-van Mölken MPMH, Oostenbrink JB, Tashkin DP, Burkhart D, Monz BU. Does quality of life of COPD patients as measured by the generic EuroQol five-dimension questionnaire differentiate between COPD severity stages? Chest 2006; 130: 1117-1128.
Shrestha N, Samir KC, Baltussen R, Kafle KK, Bishai D, Niessen LW. Practical approach to lung health in Nepal: better prescribing and reduction of cost. Trop Med Int Health 2006; 11: 765-772.
Smit F, Cuijpers P, Oostenbrink JB, Batelaan N, De Graaf R, Beekman A. Costs of nine common mental disorders: implications for curative and preventive psychiatry. J Ment Health Policy Econ 2006; 9: 193-200.
Smit F, Willemse G, Koopmanschap MA, Onrust S, Cuijpers P, Beekman A. Cost-effectiveness of preventing depression in primary care patients: randomised trial. Br J Psychiatry 2006; 188: 330-336.
Uyl-de Groot CA. Economic evaluation of cancer therapies: more and better studies will lead to better choices in cancer care. Eur J Cancer 2006; 42: 2862-2866.
Uyl-de Groot CA, McDonnell J, Ten Velde G, Radice D, Groen HJM. Cost-effectiveness of hypothetical new cancer drugs in patients with advanced small-lung cancer: results of a Markov chain model. Ther Clin Risk Manag 2006; 2: 317-323.
Visser JJ, Van Sambeek MRHM, Hunink MGM, Redekop WK, Van Dijk LC, Hendriks JM, Bosch JL. Acute abdominal aortic aneurysms: cost analysis of endovascular repair and open surgery in hemodynamically stable patients with 1-year follow-up. Radiology 2006; 240: 681-689.
Van Wijngaarden JDH, Dirks M, Dippel DWJ, Minkman M, Niessen LW. Towards effective and efficient care pathways: thrombolysis in acute ischaemic stroke. QJM 2006; 99: 267-272.
2005
Van Agthoven M, Heule-Dieleman HAG, De Boer MF, Kaanders JHAM, Baatenburg de Jong RJ, Kremer B, Leemans CR, Marres HAM, Manni JJ, Langendijk JA, Levendag PC, Tjho-Heslinga RE, De Jong JMA, Uyl-de Groot CA, Knegt PP. Evaluating adherence to the Dutch guideline for diagnosis, treatment and follow-up of laryngeal carcinomas. Radiother Oncol 2005; 74: 337-344.
Van Agthoven M, Kramer MHH, Sonneveld P, van der Hem KG, Huijgens PC, Wijermans PW, Kluin-Nelemans HC, Schaafsma MR, Biesma DH, Mattijssen V, Uyl-de Groot CA, Hagenbeek A. Cost analysis of common treatment options for indolent follicular non-Hodgkin's lymphoma. Haematologica 2005; 90: 1422-1432.
Van Agthoven M, Sonneveld P, Verdonck LF, Uyl-de Groot CA. Cost determinants in aggressive non-Hodgkin's lymphoma. Haematologica 2005; 90: 661-671.
Agyemang C, Bhopal R, Bruijnzeels M, Redekop WK. Does nocturnal blood pressure fall in people of African and South Asian descent differ from that in European white populations? A systematic review and meta-analysis. J Hypertens 2005; 23 :913-20.
Agyemang C, Bhopal R, Bruijnzeels M, Redekop WK. Does the white-coat effect in people of African and South Asian descent differ from that in White people of European origin? A systematic review and meta-analysis. Blood Press Monit 2005; 10: 243-8.
Agyemang C, Redekop WK, Owusu-Dabo E, Bruijnzeels MA. Blood pressure patterns in rural, semi-urban and urban children in the Ashanti region of Ghana, West Africa. BMC Public Health 2005; 5: 114.
Al MJ, Feenstra TL, van Hout BA. Optimal allocation of resources over health care programmes: dealing with decreasing marginal utility and uncertainty. Health Econ 2005; 14: 655-667.
Baltussen R, Brouwer W, Niessen L. Cost-effectiveness analysis for priority setting in health: penny-wise but pound-foolish. Int J Technol Assess Health Care 2005; 21: 532-4.
Baltussen R, Floyd K, Dye C. Cost effectiveness analysis of strategies for tuberculosis control in developing countries. Br Med J 2005; 331: 1364-1370.
Baltussen RM, Sylla M, Frick KD, Mariotti SP. Cost-effectiveness of trachoma control in seven world regions. Ophthalmic Epidemiol 2005; 12: 91-101.
Beersen N, Redekop WK, de Bruijn JH, Theuvenet PJ, Berg M, Klazinga NS. Quality based social insurance coverage and payment of the application of a high cost medical therapy: the case of spinal cord stimulation for chronic non-oncologic pain in The Netherlands. Health Policy 2005; 71: 107-15.
Bekkering GE, Van Tulder MW, Hendriks EJM, Koopmanschap MA, Knol DL, Bouter LM, Oostendorp RAB. Implementation of clinical guidelines on physical therapy for patients with low back pain: randomized trial comparing patient outcomes after a standard and active implementation strategy. Phys Ther 2005; 85: 544-55.
Van den Berg B, Al MJ, Brouwer WBF, Van Exel NJA, Koopmanschap MA. Economic valuation of informal care: the conjoint measurement method applied to informal caregiving. Soc Sci Med 2005; 61: 1342-1355.
Van den Berg B, Bleichrodt H, Eeckhoudt L. The economic value of informal care: a study of informal caregivers' and patients' willingness to pay and willingness to accept for informal care. Health Economics 2005; 14: 363-376.
Van den Berg B, Brouwer WBF, Van Exel NJA, Koopmanschap MA. Economic valuation of informal care: the contingent valuation method applied to informal caregiving. Health Economics 2005; 14: 169-183.
Bleichrodt H, Doctor J, Stolk EA. A nonparametric elicitation of the equity-efficiency trade-off in cost-utility analysis. J Health Econ 2005; 24: 655-678.
Braaksma M, Van Agthoven M, Nijdam W, Uyl-de Groot C, Levendag P. Costs of treatment intensification for head and neck cancer: Concomitant chemoradiation randomised for radioprotection with amifostine. Eur J Cancer 2005; 41: 2102-2111.
De Bree R, Hoekstra OS, Van der Putten L, Boers M, Uyl-de Groot CA, Leemans CR. Recidief larynxcarcinoom na radiotherapie-PET-studie: RELAPS. Ned Tijdschr Oncologie 2005; 2: 119-119.
Brouwer WBF. Ongelijkheid om positief te prikkelen: nuttig en rechtvaardig. TSG 2005; 83: 181-182.
Brouwer WBF, Van Exel NJA. Expectations about length and health related quality of life. Soc Sci Med 2005; 61: 1083-1094.
Brouwer WBF, Van Exel NJA, Van den Berg B, Van den Bos GAM, Koopmanschap MA. Process utility from providing informal care: The benefit of caring. Health Policy 2005; 74: 85-99.
Brouwer WBF, Van Exel NJA, Stolk EA. Acceptability of less than perfect health states. Soc Sci Med 2005; 60: 237-246.
Brouwer WBF, Koopmanschap MA. The friction-cost method: replacement for nothing and leisure for free? Pharmacoeconomics 2005; 23: 105-111.
Brouwer WBF, Meerding WJ, Lamers LM, Severens JL. The Relationship between Productivity and Health-Related QOL: An Exploration. Pharmacoeconomics 2005; 23: 209-18.
Brouwer WBF, Niessen LW, Postma MJ, Rutten FFH. Need for differential discounting of costs and health effects in cost effectiveness analyses. BMJ 2005; 331: 446-448.
Brouwer WBF, Rutten FFH. Optimale zorg dient onafhankelijk te worden vastgesteld, juist nu! TSG 2005; 83: 326-329.
Cohen JP. Emergence of a fourth hurdle. Regulatory Affairs Journal 2005; 16: 495-499.
Cohen JP, Paquette C, Cairnes C. Switching prescription drugs over-the-counter. Br Med J 2005; 330: 39-42.
Decramer M, Rutten-van Molken M, Dekhuijzen PN, Troosters T, van Herwaarden C, Pellegrino R, van Schayck CP, Olivieri D, Del Donno M, De Backer W, Lankhorst I, Ardia A. Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomised placebo-controlled trial. Lancet 2005; 365: 1552-60.
Doorduijn J, Buijt I, Van der Holt B, Steijaert M, Uyl-de Groot C, Sonneveld P. Self-reported quality of life in elderly patients with aggressive non-Hodgkin's lymphoma treated with CHOP chemotherapy. Eur J Haematol 2005; 75: 116-123.
Van Exel NJ, Koopmanschap MA, Scholte Op Reimer W, Niessen LW, Huijsman R. Cost-effectiveness of integrated stroke services. QJM 2005; 98: 415-25.
Van Exel NJA, Koopmanschap MA, Van den Berg B, Brouwer WBF, Van den Bos GAM. Burden of informal caregiving for stroke patients. Identification of Caregivers at risk of adverse health effects. Cerebrovasc Dis 2005; 19: 11-17.
Feenstra TL, Hamberg-van Reenen HH, Hoogenveen RT, Rutten-van Molken MP. Cost-effectiveness of face-to-face smoking cessation interventions: a dynamic modeling study. Value Health 2005; 8: 178-90.
Goor KM, Schaafsma MR, Huijgens PC, Van Agthoven M. Economic assessment on the management of chronic lymphocytic leukaemia. Expert Opin Pharmacother 2005; 6: 1179-1189.
Groot MT, Lugtenburg PJ, Hornberger J, Huijgens PC, Uyl-de Groot CA. Cost-effectiveness of rituximab (MabThera®) in diffuse large B-cell lymphoma in the Netherlands. Eur J Haematol 2005; 74: 194-202.
Hart HE, Redekop WK, Berg M, Bilo HJ, Meyboom-de Jong B. Factors that predicted change in health-related quality of life were identified in a cohort of diabetes mellitus type 1 patients. J Clin Epidemiol 2005; 58: 1158-64.
Hart HE, Redekop WK, Bilo HJ, Berg M, Jong BM. Change in perceived health and functioning over time in patients with type I diabetes mellitus. Qual Life Res 2005; 14: 1-10.
Hoeijenbos M, Bekkering T, Lamers L, Hendriks E, van Tulder M, Koopmanschap M. Cost-effectiveness of an active implementation strategy for the Dutch physiotherapy guideline for low back pain. Health Policy 2005; 75: 85-98.
Hogan DR, Baltussen R, Hayashi C, Lauer JA, Salomon JA. Cost effectiveness analysis of strategies to combat HIV/AIDS in developing countries. Br Med J 2005; 331: 1431-1437.
Hoogendoorn M, Rutten-van Mölken MPMH, Hoogenveen RT, van Genugten MLL, Buist AS, Wouters EFM, Feenstra TL. A dynamic population model of disease progression in COPD. Eur Respir J 2005; 26: 223-233.
Hutton G, Baltussen R. Cost valuation in resource-poor settings. Health Policy Plan 2005; 20: 252-259.
Jacob-Tacken KH, Koopmanschap MA, Meerding WJ, Severens JL. Correcting for compensating mechanisms related to productivity costs in economic evaluations of health care programmes. Health Econ 200; 14: 435-43.
Klok RM, Brouwer WBF, Annemans LA, Bos JM, Postma MJ. Towards a healthier discount procedure. Exp Rev Pharmacoeconomics Outcomes Res 2005; 5: 59-63.
Koopmans GT, Donker MCH, Rutten FFH. Common mental disorders and use of general health services: a review of the literature on population-based studies. Acta Psychiatr Scand 2005; 111: 341-50.
Koopmans GT, Donker MCH, Rutten FFH. Length of hospital stay and health services use of medical inpatients with comorbid noncognitive mental disorders: a review of the literature. Gen Hosp Psychiatry 2005; 27: 44-56.
Koopmanschap MA. PRODISQ: a modular questionnaire on productivity and disease for economic evaluation studies. Expert Rev Pharmacoeconomics Outcomes Res 2005; 5: 23-28.
Koopmanschap MA, Brouwer WBF, Hakkaart-van Roijen L, Van Exel NJA. The influence of waiting time on cost-effectiveness. Soc Sci Med 2005; 60: 2501-2504.
Koopmanschap MA, Burdorf A, Jacob K, Meerding WJ, Brouwer WBF, Severens JL. Productivity and health in economic evaluation; setting the research agenda. PharmacoEconomics 2005; 23: 47-54.
Lamers LM, Meerding WJ, Severens H, Brouwer WBF. The relationship between productivity and health related quality of life: an empirical exploration in persons with low back pain. Quality of Life Research 2005; 14: 805-813.
Lamers LM, Stalmeier PFM, McDonnell J, Krabbe PFM, Van Busschbach JJ. Kwaliteit van leven meten in economische evaluaties: het Nederlands EQ-5D-tarief. Ned Tijdschr Geneeskd 2005; 149: 1574-8.
Lee KS, Brouwer WBF, Lee SI, Koo HW. Introducing economic evaluation as a policy tool in Korea: will decision makers get quality information? A critical review of published Korean economic evaluations. Pharmacoeconomics 2005; 23: 709-721.
Liedgens H, Nuijten MJC, Poulsen Nautrup B. Economic evaluation of tramadol/paracetamol combination tablets for osteoarthritis pain in The Netherlands. J Appl Ther Res 2005; 25: 785-802.
Lombarts MJMH, Klazinga NS, Redekop K. Measuring the perceived impact of implementing recommendations from external assessment: lessons from the Dutch visitatie programme for medical specialists. J Eval Clin Pract 2005; 11: 587-597.
Meerding WJ, IJzelenberg W, Koopmanschap MA, Severens JL, Burdorf A. Health problems lead to considerable productivity loss at work among workers with high physical load jobs. J Clin Epidemiol 2005; 58: 517-23.
Nijdam W, Levendag P, Noever I, Uyl-de Groot C, van Agthoven M. Cancer in the oropharynx: Cost calculation of different treatment modalities for controlled primaries, relapses and grade III/IV complications. Radiother Oncol 2005; 77: 65-72.
Nuijten MJC. Incorporation of uncertainty in health economic modelling studies. Pharmacoeconomics 2005; 23: 851-853.
Nuijten MJC, Poulsen Nautrup B. Economic evaluation of a tramadol/paracetamol combination vs. tramadol in subacute low back pain in The Netherlands. J Appl Ther Res 2005; 5: 17-28.
Oostenbrink JB, Al MJ. The analysis of incomplete cost data due to dropout. Health Econ 2005; 14: 763-776.
Oostenbrink JB, Kok ET, Verheul RM. A comparative study of resource use and costs of renal, liver and heart transplantation. Transpl Int 2005; 18: 437-43.
Oostenbrink JB, Rutten-van Mölken MPMH, Monz BU, Fitzgerald JM. Probabilistic Markov model to assess the cost-effectiveness of broncholidator therapy in COPD patients in different countries. Value Health 2005; 18: 32-46.
Oppe M, Weijnen ThJG, de Charro, FTh. Development of a questionnaire to assess the quality of care in Dutch dialysis centers from the patient's perspective. Expert Rev Pharmacoeconomics Outcomes Res 2005; 5: 255-265.
Polinder S, Meerding WJ, Van Exel NJA, Brouwer WBF. Societal discounting of health effects in cost-effectiveness analyses : the influence of life expectancy. Pharmacoeconomics 2005; 23: 791-802.
De Raad J, Redekop WK. Analysis of health factors as predictors for the functioning of military personnel: study of the factors that predict fitness for duty and medical costs of soldiers of the Royal Netherlands Army. Mil Med 2005; 170: 14-20.
Rutten FFH, Brouwer WBF, Niessen LW. Practice guidelines based on clinical and economic evidence: indispensable tools in future market-oriented health care. Eur J Health Econ 2005; 6: 91-93.
Sendi P, Brouwer WBF. Is silence golden? A test of the incorporation of the effects of ill-health on income and leisure in health state valuations. Health Econ 2005; 14: 643-647.
Sittl R, Nuijten MJC, Nautrup BP. Changes in the prescribed daily doses of transdermal fentanyl and transdermal buprenorphine during treatment of patients with cancer and noncancer pain in Germany: results of a retrospective cohort study. Clin Ther 2005; 27: 1022-1031.
Stalmeier PF, Busschbach JJ, Lamers LM, Krabbe PF. The gap effect: discontinuities of preferences around dead. Health Econ. 2005; 14: 679-85.
Steinbusch P, Van Exel NJA, Huijsman R. Ketenzorg voor CVA-patiënten. Medisch Contact 2005; 60: 200-201.
Stolk EA, Pickee SJ, Ament AHJA, Busschbach JJV. Equity in health care prioritization: an empirical inquiry into social value. Health Policy 2005; 74: 343-55.
Stolk EA, Poley MJ. Criteria for determining a basic health service package. Recent developments in The Netherlands. Eur J Health Econ 2005; 6: 2-7.
Stolk EA, Rutten FFH. The Health Benefit Basket in The Netherlands. Eur J Health Econ 2005; 6 Suppl 1: 53-57.
Uyl-de Groot CA, Buijt I, Gloudemans IJM, Ossenkoppele GJ, Van den Berg HP, Huijgens PC. Health related quality of life in patients with multiple myeloma undergoing a double transplantation. Eur J Haematol 2005; 74: 136-143.
Uyl-de Groot CA, Giaccone G. Health economics: can we afford an unrestricted use of new biological agents in gastrointestinal oncology? Curr Opin Oncol 2005; 17: 392-396.
Uyl-de Groot CA, McDonnell J, Groen HJM, Radice D, Ten Velde G. Cost-effectiveness of new drugs in patients with phase IIIB-IV non-small cell lung cancer: Results of a Markov chain model. Eur J Hosp Pharm Sci 2005; 2: 37-41.
Uyl-de Groot CA, Vermorken JB, Hanna MG Jr, Verboom P, Groot MT, Bonsel GJ, Meijer CJ, Pinedo HM. Immunotherapy with autologous tumor cell-BCG vaccine in patients with colon cancer: a prospective study of medical and economic benefits. Vaccine 2005; 23: 2379-87.
De Wolf P, Brouwer WBF, Rutten FFH. Regulating the Dutch pharmaceutical market: improving efficiency or controlling costs? Int J Health Plann Manage 2005; 20: 351-374.
2004
Van Agthoven M, Segeren CM, Buijt I, Uyl-de Groot CA, Van der Holt B, Lokhorst HM, Sonneveld P. A cost-utility analysis comparing intensive chemotherapy alone to intensive chemotherapy followed by myeloablative chemotherapy with autologous stem-cell rescue in newly diagnosed patients with stage II/III multiple myeloma; a prospective randomised phase III study. Eur J Cancer 2004; 40: 1159-1169.
Van Agthoven M, Uyl-de Groot CA, Sonneveld P, Hagenbeek A. Economic assessment in the management of non-Hodgkin's lymphoma. Expert Opin Pharmacother 2004; 5: 2529-2548.
Van Agthoven M, Wittebol S, Budel LM, Uyl-de Groot CA, Kramer MHH. Overleving van patiënten met agressief non-hodgkinlymfoom: geen verschil tussen eerstelijnsbehandeling in klinisch prospectief gerandomiseerd fase-III-onderzoek en eerstelijnsbehandeling buiten studieverband. Ned Tijdschr Geneesk 2004; 148: 88-92.
Al MJ, Brouwer WBF. Stimuleren doelmatig gebruik van zuurpompremmers in de onderhoudsbehandeling. TSG 2004; 82: 191-195.
Al MJ, Feenstra T, Brouwer WBF. Decision makers' views on health care objectives and budget constraints: results from a pilot study.Health Policy 2004; 70: 33-48.
Van den Berg B, Brouwer WBF, Koopmanschap MA. Economic evaluation of informal healthcare: an overview of methods ans applications. Eur J Health Econ 2004; 5:36-45.
Baltussen R, Knai C, Sharan M. Iron fortification and iron supplementation are cost-effective interventions to reduce iron deficiency in four subregions of the world. J Nutr 2004; 134: 2678-84.
Baltussen R, Sylla M, Mariotti SP. Cost-effectiveness analysis of cataract surgery: a global and regional analysis. Bull World Health Organ 2004; 82: 338-45.
Beersen N, Bart de Bruijn JH, Dekkers MA, Ten Have P, Hekster GB, Redekop WK, Spincemaille GH, Theuvenet PJ, Berg M, Klazinga NS. Developing a national continuous quality improvement system for neuromodulation treatment in The Netherlands. Jt Comm J Qual Saf 2004; 30: 310-21.
Bernelot Moens HJ, Van Croonenborg JJ, Al MJ, Van den Bemt PMLA, Lourens J, Numans ME. Richtlijn 'NSAID-gebruik en preventie van maagschade'. Ned Tijdschr Geneeskd 2004; 148: 604-608.
Brouwer WBF, Van Exel NJA. Discounting in decision-making: the consistency argument revisited empirically. Health Policy 2004; 67: 187-194.
Brouwer WBF, Van Exel NJA, Van de Berg B, Koopmanschap MA, Dinant HJ, Van den Bos GAM. The burden of caregiving: Evidence on objective burden, subjective burden and quality of life impacts in informal caregivers for patients with Rheumatoid Arthritis. Arthritis Rheum 2004; 51: 570-577.
Brouwer WBF, Van Nooten FE, Rutten FFH. Nog veel te winnen met betere richtlijnen. TSG 2004; 8: 523-526.
Brouwer WBF, Rutten FFH. Bittere pillen. Medisch Contact 2004; 59: 1114-1116.
Brouwer WBF, Rutten FFH. Modernisering GVS: een contradictio in terminis? TSG 2004; 7: 463-466.
Bueving HJ, Bernsen RMD, De Jongste JC, Van Suijlekom-Smit LWA, Rimmelzwaan GF, Osterhaus ADME, Rutten-van Mölken MPMH, Thomas S, Van der Wouden JC. Influenza vaccination in children with astma: randomized double-blind placebo-controlled trial. Am J Respir Crit Care Med 2004; 169: 488-493.
Bueving HJ, Bernsen RMD, De Jongste JC, Van Suijlekom-Smit LWA, Rimmelzwaan GF, Osterhaus ADME, Rutten-van Mölken MPMH, Thomas S, Van der Wouden JC. Griepvaccinatie bij kinderen met astma: een gerandomiseerd dubbelblind placebo-gecontroleerd onderzoek. Huisarts en Wetenschap 2004; 47: 491-497.
Bueving HJ, Bernsen RMD, De Jongste JC, Van Suijlekom-Smit LWA, Rimmelzwaan GF, Osterhaus ADME, Rutten-van Mölken MPMH, Thomas S, Van der Wouden JC. Does influenza vaccination exacerbate asthma in children? Vaccine 2004; 23: 91-96.
Doorduijn JK, Buijt I, Van der Holt B, Van Agthoven M, Sonneveld P, Uyl-de Groot CA. Economic evaluation of prophylactic granulocyte colony-stimulating factor during chemotherapy in elderly patients with aggressive non-Hodgkin's lymphoma. Haematologica 2004; 89: 1109-1117.
Van Exel NJA, Van den Berg B, Koopmanschap MA, Van den Bos GAM, Brouwer WBF. Informele zorg: een goed om te waarderen. TSG 2004; 82: 236-242.
Van Exel NJA, Brouwer WBF, Van den Berg B, Koopmanschap MA, Van den Bos GAM. What really matters: an inquiry into the relative importance of dimensions of informal caregiver burden. Clin Rehabil 2004; 18: 683-693.
Van Exel NJA, Scholte op Reimer WJM, Koopmanschap MA. Assessment of post-stroke quality of life in cost-effectiveness studies: the usefulness of the Barthel Index and the EuroQoL-5D. Qual Life Res 2004; 13: 427-433.
Van Exel NJA, Scholte op Reimer WJM, Brouwer WBF, Van den Berg B, Koopmanschap MA, Van den Bos GAM. Instruments for assessing the burden of informal caregiving for stroke patients in clinical practice: a comparison of CSI, CRA, SCQ and self-related burden. Clin Rehabil 2004; 18: 203-214.
Groot MT, Van Agthoven M, Löwenberg B, Willemze R, Uyl-de Groot CA. De rol van kostenanalysen in de evaluatie van de ontwikkeling van medische technologieën. De casus allogene stamceltransplantaties. Ned Tijdschr Geneeskd 2004; 148: 480-484.
Groot MT, Huijgens PC, Wijermans PJ, Uyl-de Groot CA. Costs of multiple myeloma and associated skeletal-related events in The Netherlands. Expert Rev Pharmacoeconomics Outcomes Res 2004; 4: 565-572.
Hakkaart-Van Roijen L, Hoeijenbos MB, Regeer EJ, Ten Have M, Nolen WA, Veraart CP, Rutten FF. The societal costs and quality of life of patients suffering from bipolar disorder in the Netherlands. Acta Psychiatr Scand. 2004; 110: 383-92.
Hakkaart-van Roijen L, Moll van Charante EP, Bindels PJE, Yzermans CJ, Rutten FFH. A cost study of a general practitioner hospital in the Netherlands. Eur J Gen Pract 2004; 10: 45-49.
Johns B, Baltussen R. Accounting for the cost of scaling-up health interventions. Health Econ 2004; 13: 1117-1124.
Koopmanschap MA, Van Exel NJA, Van den Bos GAM, Van den Berg B, Brouwer WBF. The desire for support and respite care: preferences of Dutch informal caregivers. Health Policy 2004; 68: 309-320.
Korthals-de Bos IBC, Smidt N, Van Tulder MW, Rutten-van Mölken MPMH, Adèr HJ, Van der Windt DAWM, Assendelft WJJ, Bouter LM. Cost effectiveness of interventions for lateral epicondylitis.: results form a randomised controlled trial in primary care. Pharmacoeconomics 2004; 22: 185-195.
McDonnell J, Goverde AJ, Vermeiden JPW. The place of the crossover design in infertility trials: a maximum likelihood approach. Hum Reprod 2004; 19: 2537-44.
Moens HJ, van Croonenborg JJ, Al MJ, van den Bemt PM, Lourens J, Numans ME; Working Group, Kwaliteitsinstituut voor de Gezondheidszorg CBO. Richtlijn 'NSAID gebruik en preventie van maagschade'. Ned Tijdschr Geneeskd 2004; 148: 604-8.
Nijdam WM, Levendag PC, Noever I, Uyl-de Groot CA, Van Agthoven M. Cost analysis comparing brachytherapy versus surgery for primary carcinoma of the tonsillar fossa and/or soft palate. Int J Radiat Oncol Biol Phys 2004; 59: 488-494.
Van Nooten F, Brouwer W. The influence of subjective expectations about length and quality of life on time trade-off answers. Health Econ 2004; 13: 819-823.
Oostenbrink JB, Rutten-van Mölken MPMH. Resource use and risk factors in high-cost exacerbations of COPD. Respir Med 2004; 98: 883-891.
Oostenbrink JB, Rutten-van Mölken MPMH, Al MJ, Van Noord JA, Vincken W. One-year cost-effectiveness of tiotropium versus ipratropium to treat chronic obstructive pulmonary disease. Eur Respir J 2004; 23: 241-249.
Ortegon MM, Redekop WK, Niessen LW. Cost-effectiveness of prevention and treatment of the diabetic foot: a Markov analysis. Diabetes Care. 2004; 27: 901-907.
Peeters AJ, Van Gogh CD, Goor KM, Verdonck-De Leeuw IM, Langendijk JA, Mahieu HF. Health status and voice outcome after treatment for T1a glottic carcinoma. Eur Arch Otorhinolaryngol 2004; 261: 534-540.
Poley MJ, Bouwmans CAM, Hanff LM, Roos PJ, Van Ineveld BM. Efficiency of different systems for medication distribution in an academic children's hospital in the Netherlands. Pharm World Sci 2004; 26: 83-89.
Poley MJ, Stolk EA, Tibboel D, Molenaar JC, Busschbach JJ. Short term and long term health related quality of life after congenital anorectal malformations and congenital diaphragmatic hernia. Arch Dis Child 2004; 89: 836-841.
De Raad J, Redekop WK. A comparison between two systems for pre-employment medical assessment in the Royal Netherlands Army by a randomized, controlled study. Mil Med. 2004; 169: 437-43.
Redekop WK. Does improved glycaemic control lead to a better short-term quality of life in diabetes mellitus type 2? J Postgrad Med 2004; 50: 194.
Redekop WK, Stolk EA, Kok E, Lovas K, Kalo Z, Busschbach JJ. Diabetic foot ulcers and amputations: estimates of health utility for use in cost-effectiveness analyses of new treatments. Diabetes Metab 2004; 30: 549-56.
Regeer EJ, Ten Have M, Rosso ML, Hakkaart-Van Roijen L, Vollebergh W, Nolen WA. Prevalence of bipolar disorder in the general population: a Reappraisal Study of the Netherlands Mental Health Survey and Incidence Study. Acta Psychiatr Scand. 2004; 110: 374-82.
Rutten FFH. Health technology assessment and policy from the economic perspective. Int J Technol Assess Health Care 2004; 20: 67-70.
Rutten FFH. L'impatto della riforma sanitaria e la politica farmaceutica in Olanda. Economia Politica del Farmaco 2004; 2: 4-9.
Rutten FFH. The impact of healthcare reform in the Netherlands. Pharmacoeconomics 2004; 22 Suppl 2: 65-71.
Schut FT, Brouwer WBF. De preferente apotheker? Jazeker! ESB 2004; 89: 266-269.
Sendi P, Al MJ, Battegay M. Optimising the performance of an outpatient setting. Swiss Med Wkly 2004; 134: 44-9.
Sendi P, Al MJ, Gafni A, Birch S. Portfolio theory and the alternative decision rule of cost-effectiveness analysis: theoretical and practical considerations. Soc Sci Med 2004; 58: 1853-1855.
Sendi P, Al MJ, Rutten FFH. Portfolio theory and cost-effectiveness analysis: a further discussion. Value Health 2004; 7: 595-601.
Sendi P, Al MJ, Zimmermann H. A risk-adjusted approach to comparing the return on investment in health care programs. Int J Health Care Finance Econ 2004; 4: 199-210.
Sendi P & Brouwer WBF. Leisure time in economic evaluation: theoretical and practical considerations. Expert Review Pharmacoeconomics Outcomes Research 2004; 4: 1-3.
Stolk EA, Van Donselaar G, Brouwer WBF, Busschbach JJ. Reconciliation of economic concerns and health policy : illustration of an equity adjustment procedure using proportional shortfall. Pharmacoeconomics. 2004; 22: 1097-1107.
Uyl-de Groot CA, Gelderblom-den Hartog J, Derksen JGM, Symons EA, Buijt I, Van der Velden J, Van Lindert ACM. Cost-effectiveness and quality of life of granulocyte-colony stimulating factor (filgrastim) after radical vulvectomy and bilateral inguino-femoral lymphadenectomy: results of a randomized clinical trial. Eur J Obstet Gynec Repr Biol 2004; 114: 77-82.
Van de Ven WPMM, Van Vliet RCJA, Lamers LM. Health-adjusted premium subsidies in the Netherlands. Health Affairs 2004; 23: 45-55.
Van Wijngaarden JDH, Scholte op Reimer WJM, Van Exel NJA, Klazinga NS, Huijsman R. Coordination between caregivers from different organizations: more continuity, better results. Acta Hospitalia 2004; 44: 21-38.
De Wit A, Brouwer WBF. Economische evaluatie van GVO-programma’s. Belangrijk, lastig en te weinig gedaan. TSG 2004; 82: 129-132.
2003
Adam T, Koopmanschap MA. Cost-effectiveness analysis: can we reduce variability in costing methods? Int J Technol Assess Health Care 2003; 19: 407-42.
Van Agthoven M, Sonneveld P, Hagenbeek A, Uyl-de Groot CA. A review of recruitment criteria, patient caracteristics and results of CHOP chemotherapy in prospective randomized phase III clinical trials for aggressive non-Hodgkin's lymphoma. Hematol J 2003; 4: 399-409.
Van den Berg B, Schut FT. Het einde van gratis mantelzorg? ESB 2003; 4413: 420-422.
Baltussen RMPM, Hutubessy RCW, Evans DB, Murray CJM. Reply to Coyle's comments on 'uncertainty in cost-effectiveness analysis: probabilistic uncertainty analysis and stochastic league tables'. Int J Technol Assess Health Care 2003; 19: 682-4.
Bleichrodt H, Crainich D, Eeckhoudt L. The effect of comorbidities on treatment decisions. J Health Econ 2003; 22: 805-820.
Bleichrodt H, Crainich D, Eeckhoudt L. Comorbidities and the willingness to pay for health improvements. Journal of Public Economics 2003; 87: 2399-2406.
Bleichrodt H, Miyamoto J. A characterization of quality-adjusted life-years under cumulative prospect theory. Mathematics of Operations research 2003; 28: 181-193.
Bleichrodt H, Pinto JL, Abellan-Perpiñan JM. A consistency test of the time trade-off. J Health Econ 2003; 22: 1037-1052.
Boonen A, Van der Heijde D, Landewe R, Guillemin F, Rutten-van Mölken MPMH, Dougados M, Mielants H, De Vlam K, Van der Tempel H, Boesen S, Spoorenberg A, Schouten H, Van der Linden Sj. Direct costs of ankylosing spondylitis and its determinants: an analysis among three European countries. Ann Rheum Dis 2003; 62: 732-740.
Boonen A, Van der Heijde D, Landewe R, Guillemin F, Spoorenberg A, Schouten H, Rutten-van Mölken MPMH, Dougados M, Mielants H, De Vlam K, Van der Tempel H, Van der Linden Sj. Costs of ankylosing spondylitis in three European countries: the patient's perspective. Ann Rheum Dis 2003; 62: 741-747.
Bouwmans C, Bandel A, Sol J, Custers T, Van Ineveld B, Klazinga N. Toepasbaarheid van een kwaliteitsmodel. Reduceren van vermijdbare kosten bevordert kwaliteit voor patiënt. Kwaliteit in Beeld 2003; 12-14.
Brouwer WBF, Rutten FFH. Besparen in de praktijk. Medisch Contact 2003; 58: 1406-1408.
Brouwer WBF, Rutten FFH. The missing link: on the line between C and E. Health Economics 2003; 12: 629-636.
Brouwer WBF, van Exel NJA, Hermans B, Stoop A. Should I stay or should I go? Waiting lists and cross-border care in the Netherlands. Health Policy 2003; 63: 289-98.
Brouwer WBF, Hulst E, van Nooten FE, Rutten FFH. Generieke substitutie. Wat zijn de bevoegdheden van arts, apotheker en patiënt? TSG 2003; 3: 162-165.
Brouwer WBF, Buijsen M, Rutten FFH. Op naar een nationaal instituut voor effectiviteit en doelmatigheid in de zorg. TSG 2003; 5: 293-296.
Brouwer WBF. Regeren is vooruitzien, niet achterom kijken. TSG 2003; 6: 307-308.
Buijt I, Al MJ, Rutten FFH. Protonprompremmers, kostenremmers? Kosten en effecten van esomeprazol bij de behandeling van refluxziekte. Pharmaceutisch Weekblad 2003; 41: 1428-29.
Buijt I, Al MJ, Rutten FFH. Protonpompremmers, kostenremmers? Kosten en effecten van esomeprazol bij de behandeling van refluxziekte. Pharmaceutisch Weekblad 2003; 35: 1194-99.
Custers T, Van Ineveld BM, Sol JCA, Klazinga NS. Kosten en baten, een bekostigingsstructuur ter ondersteuning van het kwaliteitsbeleid. Medisch Contact 2003; 58: 912-914.
Custers T, Van Ineveld B, Bouwmans C, Klazinga N. Een kwaliteitskostenmodel voor de zorg. De economische kant van kwaliteitsverbetering. Kwaliteit in Beeld 2003; 15-18.
Doorduijn JK, Van der Holt B, Van Imhoff GW, Van der Hem KG, Kramer MHH, Van Oers MHJ, Ossenkoppele GJ, Schaafsma MR, Verdonck LF, Verhoef GEG, Steijaert MMC, Buijt I, Uyl-de Groot CA, Van Agthoven M, Mulder AH, Sonneveld P. CHOP compared with CHOP plus granulocyte colony-stimulating factor in elderly patients with aggressive non-Hodgkin's lymphoma. Journal of Clinical Oncology 2003; 21: 3041-3050.
Van Exel NJA, Koopmanschap MA, Brouwer WBF. Patiënt naar huis, zorg voor thuis. VGE Infobulletin 2003; 20: 15-16.
Van Exel NJA, Van den Berg B, Van den Bos GAM, Koopmanschap MA, Brouwer WBF. Mantelzorg in Nederland: een situatieschets. VGE Infobulletin 2003; 20: 10-13.
Van Exel NJA, Koopmanschap MA, Brouwer WBF. Kostbaar ontslag. Medisch Contact 2003; 58: 1272-1274.
Van Exel NJA, Koopmanschap MA, van Wijngaarden JDH, Scholte op Reimer WJM. Costs of stroke and stroke services: Determinants of patient costs and a comparison of costs of regular care organised in stroke services. Cost Eff Resour Alloc 2003; 1: 2.
Van Exel NJA, Brouwer WBF. Jeugdroken: rol voor overheid en ouders. Onderzoek in het kort. TSG 2003; 1: 24-26.
Goor KM, Mahieu HF, Leemans CR, Peeters AJGE, Langendijk JA, Van Agthoven M. Decorticatie met CO2-laser; een doelmatig alternatief voor radiotherapie in de behandeling van Tia-carnicomen van de glottis. Ned Tijdschr Geneesk 2003; 147: 1177-81.
Groot MT, Ossenkoppele GJ, Kramer MHH, van den Boom G, Huijgens PC, Uyl-de Groot CA. Medicamenteuze behandeling van chronische myeloïde leukemie: een kosteneffectiviteitsanalyse van 1e- en 2e-lijnsbehandeling. Ned Tijdschr Geneesk 2003; 147: 1460-1465.
Groot MT, Boeken Kruger CGG, Pelger RCM, Uyl-de Groot CA. Costs of prostate cancer, metastatic to the bone, in the Netherlands.European Urology 2003; 43: 226-232.
Hart HE, Bilo HJ, Redekop WK, Stolk RP, Assink JH, Meyboom-de Jong B. Quality of life of patients with type I diabetes mellitus. Qual Life Res 2003; 12: 1089-97.
Hart HE, Redekop WK, Assink JH, Meyboom-de Jong B, Bilo HJ. Health related quality of life in patients with newly diagnosed type I diabetes. Diabetes Care 2003; 26: 1319-20.
Jacobi CE, Van den Berg B, Boshuizen HC, Rupp I, Dinant HJ, Van den Bos GAM. Dimension-specific burden of caregiving among partners of rheumatoid arthritis patients. Rheumatology 2003; 42: 1226-1233.
Janknecht R, Al MJ, Brouwers J, Engeles L, Jansen M, Lems W, Bijlsma J, Van Riel P, Van der Tempel H, Wesdorp J. NSAID's bij reumatoïde artritis of artrose: preparaatkeuze met behulp van de SOJA-methode. Modern Medicine 2003; 10: 765-790.
Koopmanschap MA, Rutten FFH. The drug budget silo mentality: the Dutch case. Value in Health 2003; 6 Suppl 1: 46-51.
Korthals-de Bos IBC, Hoving JL, van Tulder MW, Rutten-van Mölken MPMH, Adèr HJ, de Vet HCW, Koes BW, Vondeling H, Bouter LM. Cost effectiveness of physiotherapy, manual therapy, and general practitioner care for neck pain: economic evaluation alongside a randomised controlled trial.Br Med J 2003; 326: 911.
Lamers LM, Van Vliet RCJA, Van de Ven WPMM. Risk-adjusted capitation payment systems for health insurance plans in a competitive market. Expert Rev Pharmacoeconomics Outcomes Res 2003; 3: 541-549.
Laterveer L, Niessen LW, Yazbeck AS. Pro-poor health policies in poverty reduction strategies. Health Policy Plan 2003; 18: 138-145.
Mauskopf J, Rutten F and Schonfeld W. Cost-effectiveness league tables: valuable guidance for decision makers? Pharmacoeconomics 2003; 21: 991-1000.
Murray CJL, Lauer JA, Hutubessy RCW, Niessen L, Tomijima N, Rodgers A, Lawes CML, Evans DB. Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: a global and regional analysis on reduction of cardiovascular-disease risk. Lancet 2003; 361: 717-725.
Niessen LW, Dijkstra R, Hutubessy R, Rutten GEHM, Casparie AF. Lifetime health effects and costs of diabetes treatment. Neth J Med 2003; 61: 355-364.
Niessen LW. Verschillende wegen naar gezondheid. Tijdschr Neur Neurchir 2003; 104: 385-387.
Nuijten MJC, Rutten FFH. The incorporation of potential confounding variables in Markov models. Pharmacoeconomics 2003;21(13):941-950.
Oostenbrink JB, Al MJ, Rutten-van Mölken MPMH. Methods to analyse cost data of patients who withdraw in a clinical trial setting. Pharmacoeconomics 2003; 15: 1103-1112.
Oostenbrink JB, Buijs-Van der Woude T, Van Agthoven M, Koopmanschap MA, Rutten FF. Unit costs of inpatient hospital days. Pharmacoeconomics 2003; 21: 263-271.
Oostenbrink R, Oostenbrink JB, Moons KGM, Derksen-Lubben G, Grobbee D, Redekop WK, Moll HA. Application of a diagnostic decision rule in children with meningeal signs: a cost-minimization study. Int J Technol Assess Health Care 2003; 19: 698-704.
Otto SJ, Fracheboud J, Looman CWN, Broeders MJM, Boer R, Hendriks JHCL, de Koning HJ, The national evaluation team for breast cancer screening and Van Ineveld BM. Initiation of population-based mammography screening in Dutch municipalities and effect on breast-cancer mortality: a systematic review. Lancet 2003; 361: 1411-1417.
Paolucci F, Brouwer WBF. Introduzione ad alcuni aspetti di economia sanitaria. (Introduction to health economics as a field of research - in Italian). Quaderni Associazione Culturale Pediatri 2003; 5: 25-27.
Polak BCP, Crijns H, Casparie AF, Niessen LW. Cost-effectiveness of glycemic control and ophthalmological care in diabetic retinopathy. Health Policy 2003; 64: 89-97.
Redekop WK, McDonnell J, Verboom P, Lovas K, Kalo Z. The cost effectiveness of Apligraf treatment of diabetic foot ulcers, Pharmacoeconomics 2003; 21: 1171-83.
Rutten FFH. Meer investeren in klinisch uitkomstenonderzoek. Conceptuur 2003; 34: 3.
Rutten-van Mölken MPMH. De toekomstige ziektelast van COPD. Patient Care 2003; 30: 23-27.
Segeren CM, Sonneveld P, van der Holt B, Vellenga E, Croockewit AJ, Verhoef GE, Cornelissen JJ, Schaafsma MR, van Oers MH, Wijermans PW, Fibbe WE, Wittebol S, Schouten HC, van Marwijk Kooy M, Biesma DH, Baars JW, Slater R, Steijaert MM, Buijt I, Lokhorst HM; Dutch-Belgian Hemato-Oncology Cooperative Study Group. Overall and event-free survival are not improved by the use of myeloablative therapy following intensified chemotherapy in previously untreated patients with multiple myeloma: a prospective randomized phase 3 study. Blood 2003; 6: 2144-2151.
Sendi P, Al MJ, Gafni A, Birch S. Optimizing a portfolio of health care programs in the presence of uncertainty and constrained resources. Soc Sci Med 2003; 57: 2207-2215.
Sendi P, Al MJ. Revisiting the decision rule of cost-effectiveness analysis under certainty and uncertainty. Soc Sci Med 2003; 57: 969-974.
Stolk EA, Busschbach JJV. Are patients and the general public like-minded about the effect of erectile dysfunction on quality of life? Urology 2003; 61: 810-815.
Stolk EA, Busschbach JJV. Validity and feasibility of the use of condition-specific outcome measures in economic evaluation. Qual Life Res 2003;12:363-371.
Verboom P, van Tinteren H, Hoekstra OS, Smit EF, van den Bergh JH, Schreurs AJ, Stallaert RA, van Velthoven PC, Comans EF, Diepenhorst FW, van Mourik JC, Postmus PE, Boers M, Grijseels EW, Teule GJ, Uyl-de Groot CA. Cost-effectiveness of FDG-PET in staging non-small cell lung-cancer: the PLUS study. Eur J Nucl Med Mol Imaging 2003; 11: 1444-1449.
2002
Van Agthoven M, Faber LM, Uyl-De Groot CA, Sonneveld P, Verdonck LF, Willemze R, Kluin-Nelemans JC, Lowenberg B, Huijgens PC. Cost analysis of CHOP (-like) chemotherapy regimens for patients with newly diagnosed aggressive non-Hodgkin's lymphoma. Eur J Haematol 2002; 69: 213-220.
Van Agthoven M, Groot MT, Verdonck LF, Lowenberg B, Schattenberg AV, Oudshoorn M, Hagenbeek A, Cornelissen JJ, Uyl-de Groot CA, Willemze R. Cost analysis of HLA-identical sibling and voluntary unrelated allogeneic bone marrow and peripheral blood stem cell transplantation in adults with acute myelocytic leukaemia or acute lymphoblastic leukaemia. Bone Marrow Transplant 2002; 30: 243-51.
Van Agthoven M, Uyl-de Groot CA, Fokkens WJ, van de Merwe JP, Busschbach JJV. Cost analysis of regular and filgrastim treatment in patients with refractory chronic rhinosinusitis. Rhinology 2002; 40: 69-74.
Van den Berg B, Rutten FFH. Meten en evalueren in de zorg. ESB 2002; 4371: 581-583.
Van den Berg B. En zij leefden nog lang en gezond. ESB 2002; 4388: 892.
Bishai D, Niessen LW, Shresta M. Local government and community financing in primary care: evidence from Nepal. Health Policy Plan 2002; 17(2):202-206.
Bleichrodt H, A new explanation for the difference between time trade-off utilities and standard gamble utilities. Health Econ 2002; 11: 447-465.
Bleichrodt H, Schmidt U. A context-dependent model of the gambling effect. Management Science 2002; 48: 802-812.
Bleichrodt H, Herrero C, Pinto JL. A proposal to solve the comparability problem in cost-utility analysis. J Health Econ 2002; 21: 397-403.
Bleichrodt H, Quiggin J. Life-cycle preferences over consumption and health: a reply to Klose. J Health Econ 2002; 21: 167-168.
Bleichrodt H, Pinto JL. Loss aversion and scale compatibility in two-attribute trade-offs. Journal of Mathematical Psychology 2002; 46: 315-337.
Boonen A, van der Heijde D, Landewé R, Spoorenberg A, Schouten H, Rutten-van Mölken M, Guillemin F, Dougados M, Mielants H, de Vlam K, van der Tempel H, van der Linden Sj. Work status and productivity costs due to anklosing spondylitis: comparison of three European countries. Ann Rheum Dis 2002; 61: 429-437.
Bouwmans CAM, Grijseels EWM, Braat DDM, Evers JLH, Hemrika DJ. Indicaties voor in-vitrofertilisatie: vergelijking van de Nederlandse richtlijnen met de gepubliceerde onderzoeksresultaten. Ned Tijdschr Geneeskd 2002; 146: 2339-42.
Brouwer WBF, van Exel NJA, Stoop AP. Grensoverschrijdende zorg niet in trek. ESB 2002; 87: 30-31.
Brouwer WBF, Rutten FFH. Een gouden pil voor apothekers. Generiek voorschrijven is nauwelijks kostenbesparend. Medisch Contact 2002; 57.
Brouwer WBF, Rutten FFH. Geef de dokter maar de schuld. Beleidsconclusies over voorschrijfgedrag schieten tekort. Medisch Contact 2002; 57.
Brouwer WBF, van Exel NJA, Koopmanschap MA, Rutten FFH. Productivity losses before and after absence: as important as common? Health Policy 2002; 61: 173-187.
Van Exel NJA, Rienstra S, Gommers M, Pearman A, Tsamboulas D. EU involvement in TEN development: network effects and European value added. Transport Policy 2002; 9: 299-311.
Van Exel IM, van Exel NJA, Brouwer WBF. Het notariaat aan banden. ESB 2002; 22: 151-153.
Feenstra TL, Rutten-van Mölken MPMH, Jager JC, van Essen-Zandvliet LEM. Cost effectiveness of guideline advice for children with astma: a literature review. Pediatr Pulmonol 2002; 34: 442-454.
Groot MT, Vanoverbeke N, Annemans L, Uyl-de Groot CA. Gemetastaseerd colorectaal carcinoom, de kosten van twee behandelingen vergeleken. Pharmaceutisch Weekblad 2002; 137: 714-721.
Huijsman R, van Wijngaarden JDH, Scholte op Reimer WJM, van Putte-Boon C, Klazinga NS, van Exel NJA, Niessen LW, Koopmanschap MA. Van units naar ketenzorg. Medisch Contact 2001; 56: 1765-1768.
Huijsman R, Scholte op Reimer WJM, Klazinga NS, van Wijngaarden JDH, van Exel NJA, van Putte-Boon C, Koopmanschap MA, Niessen LW. Stroke service: Edisse-studie onderbouwt noodzaak van landelijke implementatie van CVA-ketenzorg. Kwaliteit in Beeld 2002; 12: 8-12.
Kok ET, McDonnell J, Stolk EA, Stoevelaar HJ, Busschbach JJV. The valuation of the international prostate symptom score (IPSS) for use in economic evaluations. Eur Urol 2002; 42: 491-497.
Koopmanschap MA. Coping with type II diabetes: the patient's perspective. Diabetologia 2002; 45: S18-S22.
Lekkerkerker F, Rutten FFH. Drug licensing requirements are changing! Comment on Drummond's short paper. Eur J Health Econ 2002; 3: 141-142.
Levendag PC, Nijdam WM, van Agthoven M, Uyl-de Groot CA. Chemotherapy and high-dose-rate brachytherapy in the management of advanced cancers of the nasopharynx: clinical impact of high technology - is it worth the cost? Brachyther 2002; 1: 11-20.
McDonnell J, Goverde AJ, Rutten FFH, Vermeiden JPW. Multivariate Markov chain analysis of the probability of pregnancy in infertile couples undergoing assisted reproduction. Hum Reprod 2002; 17: 103-106.
Mills A, Antonius R, Daniel J, Gray H, Haqq E and Rutten F. The distribution of health planning and management responsibilities between centre and periphery: historical patterns and reform trends in four Caribbean territories. Health Policy 2002; 62: 11-30.
Nuijten MJC, Rutten FFH. Combining a budgetary-impact analysis and a cost-effectiveness analysis using decision-analytic modelling techniques. Pharmacoeconomics 2002; 20: 855-867.
Oostenbrink JB, Koopmanschap MA, Rutten FFH. Standardisation of costs. The Dutch manual for costing in economic evaluation. Pharmacoeconomics 2002; 20(7): 443-454.
Oostenbrink R, Oostenbrink JB, Moons KGM, Derksen-Lubsen G, Grobbee DE, Redekop WK, Moll HA. Cost-utility analysis of patient care in children with meningeal signs. Int J Technol Assess Health Care 2002; 18: 485-496.
Poley MJ, Stolk EA, Brouwer WBF, Busschbach JJV. Ziektelast als criterium. Overheid wil geneesmiddelenpakket beperken. Medisch Contact 2002; 57: 1697-1700.
Poley MJ, Stolk EA, Brouwer WBF, Busschbach JJV. Ziektelast als uitwerking van het criterium 'noodzakelijkheid' bij het maken van keuzen in de zorg. Ned Tijdschr Geneeskd 2002; 146: 2312-2315.
Poley MJ, Stolk EA, Tibboel D, Molenaar JC, Busschbach JJ. The cost-effectiveness of treatment for congenital diaphragmatic hernia. J Pediatr Surg 2002; 37: 1245-52.
Redekop K, Koopmanschap MA, Rutten GEHM, Wolffenbuttel B, Stolk RP, Niessen LW. Resource consumption and costs in Dutch patients with Type 2 diabetes mellitus. Diabet Med 2002; 19: 246-253.
Redekop K, Koopmanschap MA, Rutten GEHM, Wolffenbuttel B, Stolk RP, Niessen LW. Health related quality of life and treatment satisfaction in Dutch patients with type 2 diabetes. Diabetes Care 2002; 25: 458-63.
Rutten FFH, Lapré R, Antonius R, Dokoui S, Haqq E, Roberts R, Mills A. Financing of health care in four Caribbean territories: a comparison with reforms in Europe. Health Policy 2002; 61: 49-59.
Rutten FFH, Brouwer WBF. Meer zorg bij beperkt budget; een pleidooi voor een betere inzet van het doelmatigheidscriterium. Ned Tijdschr Geneeskd 2002; 146: 2254-8.
Stolk EA, Brouwer WBF, Busschbach JJV. Rationalising rationing: economic and other considerations in the debate about funding of Viagra. Health Policy 2002; 59: 53-63.
Van Tubergen A, Boonen A, Landewé R, Rutten-van Mölken M, van der Heijde D, Hidding A, van der Linden Sj. Cost effectiveness of combined spa-exercise therapy in ankylosing spondylitis: a randomized controlled trial. Arthritis Rheum 2002; 47: 459-467.
Verboom P, Hakkaart-van Roijen L, Sturkenboom M, de Zeeuw R, Menke H, Rutten FFH. Epidemiology and Health Services Research. The cost of atopic dermatitis in the Netherlands: an international comparison. Br J Dermatol 2002; 147: 716-724.
Vrijland WW, van den Tol MP, Luijendijk RW, Hop WC, Busschbach JJV, De Lange DC, Van Geldere D, Rottier AB, Vegt PA, IJzermans JN, Jeekel J. Randomized clinical trial of non-mesh versus mesh repair of primary inguinal hernia. Br J Surg 2002; 89: 293-297.
2001
Van Agthoven M, Fokkens WJ, van de Merwe JP, van Bolhuis EM, Uyl-de Groot CA, Busschbach JJV. Quality of life of patients with refractory chronic rhinosinusitis, effects of filgrastim treatment. Am J of Rhinol 2001; 15: 231-238.
Van Agthoven M, van Ineveld BM, de Boer MF, Leemans CR, Knegt PP, Snow GB, Uyl-de Groot CA. The costs of head and neck oncology. primary tumours, recurrent tumours and long-term follow-up. Eur J Cancer 2001; 37: 2204-2211.
Van Agthoven M, Metselaar HJ, Tilanus HW, de Man RA, IJzermans JNM, van Ineveld BM. A comparison of the costs and effects of liver transplantation for acute and for chronic liver failure. Transpl Int 2001; 14: 87-94.
Van Agthoven M, Vellenga E, Fibbe WE, Kingma T, Uyl-de Groot CA. Cost analysis and quality of life assessment comparing patients undergoing autologous peripheral blood stem cell transplantation or autologous bone marrow transplantation for refractory or relapsed non-Hodgkin's lymphoma or Hodgkin's disease: a prospective randomised trial. Eur J Cancer 2001; 37 (14): 1781-1789.
Bleichrodt H, Johannesson M. Time Preference for Health: A Test of Stationarity versus Decreasing Timing Aversion. J Math Psychol 2001; 45: 265-282.
Bleichrodt H, Pinto JL, Wakker PP. Making descriptive use of prospect theory to improve the prescriptive use of expexted utility. Management Science 2001; 47: 1498-1514.
Bleichrodt H. Probability weighting in choice under risk: an empirical test. The journal of Risk and Uncertainty 2001; 23 : 185-198.
Bouwmans CAM, Bandel AP, Sol JCA, Ineveld BM van, Klazinga NS. Met het ziekenhuis de lucht in? ZM Magazine 2001; 17: 13-17.
Brouwer WBF, Rutten FFH. Health economics: a bridge over troubled water. Eur J Public Health 2001; 11: 234-36.
Brouwer WBF, Van Exel NJA. Zorgelijk vervoersbeleid. ESB 2001; 86: 328-29.
Brouwer WBF, Hermans HEGM. Europese regelgeving grijp in op nationaal zorgstelsel. TSG 2001;79: 176-79.
Brouwer WBF, Schut FT. Ethische dilemma’s in het nieuwe zorgstelsel. ESB Dossier 2001; 86: D7.
Brouwer WBF, Stoop AP. Maak het wachten dragelijker: vaste afspraken binnen maximum levertijden. Medisch Contact 2001; 56: 908-9.
Brouwer WBF, Hermans HEGM, Van Doorslaer EKA. Zorg in en om Europa. ZorgVisie 2001; 31: 24-9.
Brouwer WBF, Rutten FFH. GVS geeft verkeerde signalen. ESB 2001; 86: 884-886.
Busschbach JJV, Doerga EV, Kamerling MM, Plandsoen MJ, Vleuten HAvd, Vliet Av, Wel PC vd, IJperen MJv. Verpleeghuiszorg thuis kan doelmatig: Ouderen stellen lagere eisen aan veiligheid en service bij extramurale verpleeghuiszorg. Ouderenzorg 2001; 4: 24-6.
Busschbach JJV, Van Hout BA. Snel verdiend. Nieuwe medicatie kan kosteneffectief zijn. Medisch Contact 2001; 56: 1815-7.
Chevat C, Pena BM, Al MJ, Rutten FFH. Healthcare resource utilisation and costs of treating NSAID-associated gastrointestinal toxicity. A multinational perspective. Pharmacoeconomics 2001; 19 Suppl 1: 17-32.
Van Exel NJA, Brouwer WBF. Lekker belangrijk. ESB 2001; 86: 155-57.
Feenstra TL, Van Genugten MLL, Hoogenveen RT, Wouters EF, Rutten-van Mölken MPMH. The impact of aging and smoking on the future burden of chronic obstructive pulmonary disease. A model analysis in the Netherlands. Am J Respir Crit Care Med 2001; 164: 590-6.
Gorter JW, Oostenbrink JB, Tangelder MJD (for the Stroke Prevention in Reversible Ischemia Trial (SPIRIT) Study Group and the Dutch BOA Study Group). Costs of outpatient anticoagulant treatment in patients with cerebral and peripheral arterial occlusive disease. Thromb Haemost 2001; 85: 52-6.
Hakkaart-van Roijen L, Verboom P, Redekop WK, Touw KR, Rutten FFH. The cost effectiveness of tapered versus abrupt discontinuation of oral cyclosporin microemulsion for the treatment of psoriasis. Pharmacoeconomics 2001; 19: 599-608.
Harris A, Buxton M, O'Brien B, Rutten F, Drummond M. Using economic evidence in reimbursement decisions for health technologies: experience in 4 countries. Expert Review Pharmacoeconomics Outcomes Research 2001; 1: 7-12.
Van Hout BA, Simoons ML. Cost-effectiveness of HMG coenzyme reductase inhibitors. Whom to treat? Eur Heart J 2001; 22: 751-61.
Jansen R, Redekop WK, Rutten FFH. Cost effectiveness of continuous terbinafine compared with intermittent itraconazole in the treatment of dermatophyte toenail onychomycosis: an analysis of based on results from the L.I.ON. study. Lamisil versus Itraconazole in Onychomycosis. Pharmacoeconomics 2001; 19: 401-10.
Kanis JA, Oden A, Johnell O, Jonsson B, de Laet C, Dawson A. The burden of osteoporotic fractures: a method for setting intervention thresholds. Osteoporos Int 2001; 12: 417-27.
Kanis JA, Dawson A, Oden A, Johnell O, de Laet C, Jonsson B. Cost-effectiveness of preventing hip fracture in the general female population. Osteoporos Int 2001; 12: 356-61.
Li N, van Agthoven M, Willemse PHB, Uyl-de Groot CA. A Cost-Utility Analyses Comparing Second-line Chemotherapy Schemes In Patients With Metastatic Breast Cancer. Anticancer Drugs 2001; 12: 533-40.
McDonnell J, Busschbach JJV, Kok E, Van Exel J, Stolk E, Koopmanschap M, Rutten FFH. Lower urinary tract symptoms suggestive of benign prostatic obstruction - Triumph: health-economical analysis. Eur Urol 2001; 39: 37-41.
McDonnell J, Redekop WK, Roer Nvd, Goes E, Ruitenberg A, Busschbach JJV, Breteler MMG, Rutten FFH. The cost of treatment of Alzheimers’s disease in The Netherlands. A regression-based simulation model. Pharmacoeconomics 2001;19:379-90.
Oostenbrink JB, Rutten-van Mölken MPMH, Sluyter-Opdenoordt TS. Resource use and costs of patients with glaucoma or ocular hypertension: a one-year study based on retrospective chart review in the Netherlands. J Glaucoma 2001; 10: 184-91.
Oostenbrink JB, Tangelder MJD, Busschbach JJv, Van Hout BA, Buskens E, Algra A, Lawson JA, Eikelboom BC; Dutch Bypass Oral anticoagulants or Aspirin (BOA) Study Group. Cost-effectiveness of oral anticoagulants versus aspirin in patients after infrainguinal bypass surgery, J Vasc Surg 2001; 34: 254-62.
Poley MJ, Stolk EA, Langemeijer RATM, Molenaar JC, Busschbach JJV. The cost-effectiveness of neonatal surgery and subsequent treatment for congenital anorectal malformations. J Pediatr Surg 2001; 36: 1471-8.
Rhemrev JPT, Lens JW, McDonnell J, Schoemaker J, Vermeiden JPW. The postwash total progressively motile cell count is a reliable predictor of total fertilization failure during in-vitro fertilization treatment. Fertil Steril 2001; 76: 884-891.
Ruitenberg A, Kalmijn S, de Ridder MAJ, Redekop WK, van Harskamp F, Hofman A, Launer LJ, Breteler MM. Prognosis of Alzheimer's Disease: The Rotterdam Study. Neuroepidemiology 2001; 20: 188-195.
Rutten FFH, Busschbach JJV. How to define a basic package of health services for a tax funded or social insurance based health care system? (editorial) Eur J Health Econ (HEPAC) 2001; 2: 45-6.
Rutten FFH, Bleichrodt H, Brouwer WBF, Koopmanschap M, Schut E. Book review: handbook of health economics. J Health Econ 2001; 20: 855-879.
Serruys PW, Unger F, Sousa JE, Jatene A, Bonnier HJ, Schonberger JP, Buller N, Bonser R, Brand MJv d, Herwerden LAv, Morel MA, van Hout BA. Arterial Revascularization Therapies Study Group. Comparison of coronary-artery bypass surgery and stenting for the treatment of multivessel disease. N Engl J Med 2001; 344: 1117-24.
Stolk EA, Busschbach JJV. A comparison of the EuroQol and the Health Utilities Index in patients treated for congenital anomalies. Eur J Health Econ (HEPAC) 2001; 2: 54-60.
Stooker T, van Acht JW, van Barneveld EM, van Vliet RCJA, van Hout BA, Hessing DJ, Busschbach JJV. Costs in the Last Year of Life in the Netherlands. Inquiry 2001; 38: 73-80.
Stoop AP, Brouwer WBF. Huidige discussie over wachtlijsten niet zinvol. Medisch Contact 2001; 56: 1610-1612.
Suryapranata H, Ottervanger JP, Nibbering E, Van 't Hof AW, Hoorntje JC, De Boer MJ, Al MJ, Zijlstra F. Long term outcome and cost-effectiveness of stenting versus balloon angioplasty for acute myocaridal infarction. Heart 2001; 85: 667-71.
van Tinteren H, Hoekstra OS, Smit EF, Verboom P, Boers M; PLUS Study Group. Toward less futile surgery in non-small cell lung cancer? A randomized clinical trial to evaluate the cost-effectiveness of positron emission tomography. Control Clin Trials 2001; 22: 89-98.
Touw CR, Hakkaart-van Roijen L, Verboom P, Paul C, Rutten FFH, Finlay AY. Quality of life and clinical outcome in psorias patients using intermittent cyclosporin. Br J Dermatol 2001; 144: 967-72.
Uyl-De Groot CA, Gelderblom-Den Hartog J, Huijgens PC, Willemze R, Ineveld BM van. Costs of diagnosis, treatment, and follow up of patients with acute myeloid leukemia in the netherlands. J Hematother Stem Cell Res 2000; 10: 187-92.
Vellenga E, van Agthoven M, Croockewit AJ, Verdonck LF, Wijermans PJ, van Oers MH, Volkers CP, van Imhoff GW, Kingma T, Uyl-De Groot CA, Fibbe WE. Autologous peripheral blood stem cell transplantation in patients with relapsed lymphoma results in accelerated haematopoietic reconstitution, improved quality of life and cost reduction compared with bone marrow transplantation: the Hovon 22 study. Br J Haematol 2001; 114: 319-326.
Verkerk MA, Busschbach JJV, Karssing ED. Health-related quality of life research and the capability approach of Amartya Sen. Qual Life Res 2001; 10: 49-55.
2000
Al MJ, van Hout BA. A Bayesian approach to economic analyses of clinical trials: the case of stenting versus balloon angioplasty. Health Econ 2000; 9: 599-609.
Van den Berg B, Brouwer WBF, Koopmanschap MA. Recht op thuiszorg. Hoe zijn de wachttijden op korte termijn te reduceren? Medisch Contact 2000; 55: 93-6.
Van den Berg B, Mot, ES. Honorering, verwijsgedrag en prikkels. ESB 2000; 85: 791-3.
Bleichrodt H, Pinto JL. A Parameter-Free Elicitation of the Probability Weighting Function in Medical Decision Analysis. Management Science 2000; 46: 1485-1496.
Van den Boom G, Rutten-van Mölken MPMH, Folgering H, Weel C van, Schayck CP van. The economic effects of screening for obstructive airway disease: an economic analysis of the DIMCA program. Prev Med 2000; 30: 302-8.
Brouwer WBF, van Hout BA, Rutten FFH. A fair approach to discounting future effects: taking a societal perspective. J Health Serv Res Policy 2000; 5: 114-8.
Brouwer WBF, Koopmanschap MA. On the Economic Foundations of CEA. Ladies and gentlemen, take your positions! J Health Econ 2000; 19: 439-59.
Brouwer WBF. Het verdelen van de schaarste - over het nut van gezondheidseconomisch onderzoek. Medisch Contact 2000; 55: 939-42.
Brouwers JRBJ, van Roon EN, Postma M, Al MJ. Kosten-effectiviteit van NSAID’s: Altijd gastroprotectie? Pharmaceutisch Weekblad 2000; 135: 172-5.
Buijs HPAM, Busschbach JJV, van Doorn HHJL, van Dorp B, Grootscholten ECM, Prins CD, Slijkhuis AY, van Urk LE,Voncken R. Gelijke monniken, diverse kappen. Variatie in indicaties voor thuiszorg. Medisch Contact 2000; 55: 1395-7.
Curran D, Aaronson N, Standaert B, Molenberghs G, Therasse P, Ramirez A, Koopmanschap MA, Erder H, Piccart M. Summary measures and statistics in the analysis of quality of life data: an example from an EORTC-NCIC-SAKK locally advanced breast cancer study. Eur J Cancer 2000; 36: 834-44.
Van Doorslaer EKA, Brouwer WBF. Waiting lists in The Netherlands: workers first? J Health Serv Res Policy 2000; 5: 129-30.
EhrnBorg C, Hakkaart-van Roijen L, Jönsson B, Rutten FFH, Bengtsson BÅ, Rosén T. Cost of illness in adult patients with hypopituitarism. Pharmacoeconomics 2000; 17: 621-28.
Faber LM, Agthoven M, Uyl-de Groot CA, Löwenberg B, Huijgens PC. Diagnostiek en behandeling van het non-Hodgkin lymfoom in Nederland: variëteit in richtlijnen en in de praktijk. Ned Tijdschr Geneesk 2000; 144: 1223-27.
Feenstra N, Rutten G, Koopmanschap MA, Jansen R. Een gezondheidseconomische uitdaging; analyse van diabetes mellitus type 2. Medisch Contact 2000; 55: 209-12.
Fracheboud J, Boer R, van Ineveld BM, Verbeek ALM, Hendriks JHCL, Broeders MJM, de Bruyn AE, de Koning HJ, van der Maas PJ. Landelijk bevolkingsonderzoek naar borstkanker volledig ingevoerd; resultaten van de implementatiefase 1990-1997. Ned Tijdschrift Geneesk 2000; 144: 1124-1129.
Goossens MEJB, Rutten-van Mölken MPMH, Vlaeyen JWS, Van der Linden SMJP. The cost diary: a method to measure direct and indirect costs in cost-effectiveness research. J Clin Epidemiol 2000; 53: 688-95.
Goverde AJ, McDonnell J, Vermeiden JPW, Schots R, Rutten FFH, Schoemaker J. Intrauterine insemination or in vitro fertilisation in idiopathic and male subfertility: a randomised trial and cost-effectiveness analysis. Lancet 2000; 355: 13-9.
Hakkaart-van Roijen L. Maatschappelijke gevolgen van migraine in Nederland. Pharmaceutisch weekblad 2000; 135: 310-13.
Kanis JA, Johnell O, Oden A, Jonsson B, de Laet CE, Dawson A. Prediction of fracture from low bone mineral density measurements overestimates risk. Bone 2000; 26: 387-91.
Kanis JA, Johnell O, Oden A, Jonsson B, de Laet C, Dawson A. Risk of hip fracture according to the World Health Organization criteria for osteopenia and osteoporosis.Bone 2000; 27: 585-90.
Kanis JA, Johnell O, Oden A, Sernbo I, Redlund-Johnell I, Dawson A, De Laet C, Jonsson B. Long-term risk of osteoporotic fracture in Malmo. Osteoporos Int 2000; 11: 669-74.
Koopmans GT, Lamers LM. Chronic conditions, psychological distress and the use of psychoactive medications. J Psychosom Res 2000; 48: 115-123.
de Laet C, Pols HAP. Fractures in the elderly: epidemiology and demography. Baillieres Best Pract Res Clin Endocrinol Metab 2000; 14: 171-79.
McDonnell J, Meijler AP, Kahan JP, Rigter HGM, Bernstein SJ. Effect of Physician speciality on treatment recommendation to patients with coronary artery disease. Int J Technol Assess Health Care 2000; 16: 190-198.
Moerman CJ, van Hout BA, Bonneux L, Witteman JCM. Postmenopausal hormone therapy: less favourable risk-benefit ratios in healthy Dutch women. J Intern Med 2000; 248: 143-50.
Niessen LW, Dippel DWJ, Limburg M. Berekening van kosten na een beroerte en kosteneffectiviteit van 'stroke units' en van secundaire preventie, zoals aanbevolen in de herziene CBO-richtlijn 'Beroerte'. Ned Tijdschr Geneesk 2000; 144: 1959-64.
Niessen LW, Grijseels EWM, Rutten FFH: The evidence-based approach in health policy and health care delivery. Soc Science Med 2000; 51: 859-69.
Oostenbrink JB, Bandel AP, Sol JCA, van Ineveld BM. Kostprijsberekening voor bedrijfsvoering en economische evaluatie. Een vergelijking van methoden en resultaten. TSG 2000; 7: 432-38.
Oostenbrink JB, Rutten-van Mölken MPMH, Opdenoordt TS. The treatment of newly diagnosed patients with glaucoma or with ocular hypertension in The Netherlands; an observational study of costs and initial treatment success based on retrospective chart review. Doc Opthalmol 1999; 98: 285-99.
Van Os N, Niessen LW, Bilo HJG, Casparie AF, van Hout BA. Diabetes nephropathy in the Netherlands: a cost effectiveness analysis of national clinical guidelines. Health Policy 2000; 51: 35-147.
Van Os N, Niessen LW, Koopmanschap MA, van der Lei J. Gedetailleerde raming van de maatschappelijke kosten van diabetes mellitus. Ned Tijdschr Geneeskd 2000; 144: 842-46.
Van de Roer N, Goes ES, Blom M, Busschbach JJV. Een kostenmodel van de zorg voor dementerenden: thuiswonen versus opname. Tijdschr Gerontol Geriatr 2000; 31: 55-62.
Rutten FFH. Dwalingen in de methodologie. XIX. Kosten-effectiviteitsratio's. Ned Tijdschr Geneeskd 2000; 144: 311-14.
Serruys PW, de Bruyne B, Carlier S, Sousa JE, Piek J, Muramatsu T, Vrints C, Probst, P, Seabra-Gomes R, Simpson I, Voudris V, Gurne O, Pijls N, Belardi J, van Es GA, Boersma E, Morel MA, Hout van BA. Randomized comparison of primary stenting and provisional balloon angioplasty guided by flow velocity measurement. Circulation 2000; 102: 2930-7.
Stolk EA, Brouwer WBF, Busschbach JJV. Vergoeding Viagra stuit op waarden en normen. Medisch Contact 2000; 55: 626-29.
Stolk EA, Busschbach JJV, Caffa M, Meuleman EJH, Rutten FFH. Cost utility analysis of sildenafil compared with papaverine-phentolamine injections. Br Med J 2000; 320: 1165-68.
Stolk EA, Busschbach JJV, Vogels T. Performance of the EuroQol in children with imperforate anus. Qual Life Res 2000; 9: 29-38.
Stolk EA, Post HA, Rutten FFH, Molenaar JC, Busschbach JJV. Cost-effectiveness of neonatal surgery: a review. J Pediatr Surg 2000; 35: 588-92.
Uyl-de Groot CA. Cost-Effectiveness of stem-cell transplantations in non-Hodgkin's lymphoma in the Netherlands. ONE 2000; 1: 49-52.
Uyl-de Groot CA, Wait S, Buijt I. Economics and health-related quality of life in antiemetic therapy: recommendations for trial design. Eur J Cancer 2000; 36: 1522-35.
De Wit GA, Busschbach JJV, de Charro FT. Sensitivity and perspective in the valuation of health status: whose values count? Health Economics 2000; 9: 109-26.
Zwart-van Rijkom JEF, Leufkens HGM, Busschbach JJV, Broekmans AW, Rutten FFH. Differences in attitudes, knowledge and use of economic evaluations in decision-making in the Netherlands - The Dutch results from the EUROMET project. Pharmacoeconomics 2000; 18: 149-60.
1999
Bleichrodt H, Quiggin J. Life Cycle Preferences over Consumption and Health: When is Cost Effectiveness Analysis Equivalent to Cost Benefit Analysis? J Health Econ 1999; 18: 681-708.
Bleichrodt H, Rijn J van, Johannesson M. Probability Weighting and Utility Curvature in QALY Based Decision Making. J Math Psychol 1999; 43: 238-60.
Brouwer WBF, Exel NJA van, Koopmanschap MA, Rutten FFH. The valuation of informal care in Economic Appraisal; a consideration of individual choice and societal costs of time. Int J Technol Assess Health Care 1999; 15: 147-60.
Brouwer WBF, Hermans HEGM. Private clinics for employees as a Dutch solution for waiting lists: economic and legal aspects. Health Policy 1999; 47: 1-17.
Brouwer WBF, Koopmanschap MA, Rutten FFH. Productivity losses without absence: measurement validation and empirical evidence. Health Policy 1999; 48: 13-27.
Brouwer WBF, Schut FT. Priority care for employees: a blessing in disguise? Health Econ 1999; 8: 65-73.
Burger H, de Laet CE, Weel A, Hofman A, Pols HAP. Added value of bone mineral density in hip fracture risk scores. Bone 1999; 25: 369-74.
Busschbach JJV, Berg Jvd, Bruggeling A, Bruijninckx, Helderman P, Hoeijenbos M, Ruiter Md, Vliet EJv. Wie extra betaalt kan eerst. Een markt voor voorrang in de zorg. Medisch Contact 1999; 54: 1660-2.
Busschbach JJV, Heerkens HM, Moleman AHF, Oostveen JPM, Stoppelenburg A, Treples RMPM, Vrakking AM. Rechtvaardigheid niet altijd synoniem met gelijkheid. Het maatschappelijk draagvlak voor bedrijvenpoli's. Medisch Contact 1999; 54: 235-6.
Busschbach JJV, McDonnell J, Essink-Bot ML, van Hout BA. Estimating parametric relations between health description and health valuation with an application to the EuroQol instrument. J Health Econ 1999; 18: 551-71.
Busschbach JJV, McDonnell J, Tangelder MJD, Eikelboom BC, Buskens E, Algra A, Lawson JA, for the Dutch Bypass Oral Anticoagulants or Aspirin (BOA) Study Group. EuroQol values for economic modelling quality of life after infrainguinal bypass surgery, a rectification. J Vasc Surg 1999; 30: 1162-3.
Drummond M, Dubois D, Garattini L, Horrisberger B, Jönsson B, Kristiansen I, Le Pen C, Pinto C, Poulsen P, Rovira J, Rutten F, Von der Schulenburg M, Sintonen H. Current trends in the use of pharmacoeconomics and outcomes research in Europe. Value in Health 1999; 2: 232-332.
Van Enckevort PJ, Ten Vergert EM, Kingma J, Koëter GH, Rutten FFH. Factors to consider when designing phase III clinical trials involving economic evaluations. Percept Mot Skills 1999; 89: 1059-72.
Van Enckevort PJ, Ten Vergert EM, Geertsma A, Van der Bij W, De Boer WJ, Rutten FFH. Prospective cost-utility analysis of lung transplantation in the Netherlands: a comment on the pilot study by Gartner et al. J Heart Lung Transplant 1999; 18: 496-497.
Van Enckevort PJ, Ten Vergert EM, Schrantee S, Rutten FFH, De Vries EGE. Basic concepts of economic evaluation. Crit Rev Oncol Hematol 1999;32:113-124.
Goossens MEJB, Evers SMAA, Vlaeyen JWS, Rutten-van Mölken MPMH, Van der Linden SMJP. Principles of economic evaluation for interventions of chronic musculoskeletal pain. Eur J Pain 1999; 3: 343-53.
Goossens MEJB, Vlaeyen JWS, Rutten-van Mölken MPMH, Linden SMJP van der. Patient utilities in chronic musculoskeletal pain: how useful is the standard gamble method? Pain 1999; 80: 365-75.
Grijseels EWM, Goes ES, Quarles van Ufford MA, Van Hout BA. Passende medische zorg; de waarde van kosten effectiviteit, Medisch Contact, 1999; 38: 1285-6.
Groener MGH, Ineveld BM van, Byttebier G, Hout BA van, Rutten FFH. An economic evaluation of Tomudex (raltitrexed) and 5-fluorouracil plus leucovorin in advanced colorectal cancer. Anticancer Drugs 1999; 10: 283-8.
Van Hout BA, Goes ES, Grijseels EW, van Ufford MA. Economic evaluation in the field of cardiology: theory and practice. Prog Cardiovasc Dis 1999; 42: 167-73.
Kole-Snijders AMJ, Vlaeyen JWS, Goossens MEJB, Rutten-van Mölken MPMH, Heuts PHTG, Breukelen G, van Eek H. Chronic low back pain: what does cognitive coping skills training add to operant behavioral treatment? Results of a randomized clinical trial. J Consult Clin Psychol 1999; 67: 931-44.
De Laet CE, Van Hout BA, Burger H, Weel AE, Hofman A, Pols HA. Incremental cost of medical care after hip fracture and first vertebralfracture: the Rotterdam study. Osteoporos Int 1999; 10: 66-72.
Van Lent-Evers NA, Mathot RA, Geus WP, Hout BA van, Vinks AA. Impact of goal-oriented and model-based clinical pharmacokinetic dosing faminoglycosides on clinical outcome: a cost-effectiveness analysis. Ther Drug Monit 1999; 21: 63-73.
Middelman KFG, Busschbach JJV, Koorneef M, Scholten GRM. Waarom niet de sportarts? Medisch Contact 1999; 54: 912-5.
Van Os N, Niessen LW, Casparie AF, Van Hout BA. Cost-effectiveness analysis of national clinical guidelines. Diabetes 1999; 48: 1838.
Van Rijkom J, Leufkens H, Crommelin D, Rutten F, Broekmans A. Assessment of biotechnology drugs: what are the issues? Health Policy 1999; 47: 255-274.
Rutten FFH, Grijseels EWM. De voorwaarden voor invoering en financiering van nieuwe technieken. Ned Tijdschr Geneeskd 1999; 143: 2229-32.
Rutten-van Mölken MPMH, Postma MJ, Joore MA, Van Genugten M, Leidl R, Jager JC, Feenstra T. Current and future health care impact of asthma and COPD in The Netherlands. Resp Med 1999; 93: 779-87.
Rutten-van Mölken MPMH, Roos B, Van Noord JA. An empirical comparison of the St Georges Respiratory Questionnaire and the Chronic Respiratory Questionnaire in a clinical trial setting. Thorax 1999; 54: 995-1003.
Serruys PW, Unger F, van Hout BA, van den Brand MJ, van Herwerden LA, van Es GA, Bonnier JJ, Simon R, Cremer J, Colombo A, Santoli C, Vandormael M, Marshall PR, Madonna O, Firth BG, Breeman A, Morel MA, Hugenholtz PG. The ARTS study (Arterial Revascularization Therapies Study). Semin Interv Cardiol 1999; 4: 209-19.
Tangelder MJD, McDonnell J, Busschbach JJV, Buskens E, Algra A, Lawson JA, Eikelboom BC on behalf of the Dutch BOA Study Group. Quality of life after infrainguinal bypass surgery. J Vasc Surg 1999; 29: 913-9.
Uyl-de Groot CA, Ossenkoppele GJ, Buijt I, Huijgens PC. Costs of peripheral blood progenitor cell transplantation using whole blood mobilised by filgrastim as compared with autologous bone marrow transplantation in non-Hodgkin's lymphoma. Pharmacoeconomics 1999; 15: 305-11.
Uyl-de Groot CA, Ossenkoppele GJ, Buyt I, Huygens PC. Stem Cell Transplantations in Patients with Malignant Lymphoma: Costs in a Dutch University Hospital in the Period 1984-1995. J Hematother Stem Cell Res 1999; 8: 619-25.
Van der Woude T, Rutten-van Mölken MPMH, Buller HR, Brandjes DPM. Rentabilité de l'utilisation a titre prophylactique des bas de compression chez des patients presentant une thrombose veineuse profonde (The cost-effectiveness of the prophylactic uses of compression stockings in patients with deep-vein thrombosis) Phlébologie 1999; 52: 145-52.
